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ABSTRACT
SLEEP/WAKE ACTIVITY AND ENERGY EXPENDITURE IN OVERWEIGHT AND
OBESE OBSTRUCTIVE SLEEP APNEA PATIENTS: A PRE- AND POST-CPAP
COMPARISON
Pamela A. McCullough
July 27,2011
Overweight and obesity is a major contributing factor in an estimated 70% of all
obstructive sleep apnea (OSA) cases. Approximately five percent of the adult population
has OSA, and the numbers continue to soar with the rising prevalence of obesity. As a
primary therapy, continuous positive airway pressure (CPAP) has demonstrated
improvement in many comorbities associated with both OSA and obesity. Although
anecdotal and clinical references support increased energy, activity, and weight loss as a
potential benefit of CPAP treatment, there remains little evidence to endorse CPAP as a
significant weight-reduction measure for overweight and obese OSA patients. The
purpose of this study was to examine sleep/wake activity and energy expenditure, preand post-CPAP treatment, in adult overweight and obese patients with OSA. A
prospective, observational, longitudinal study design was employed to assess 24-hour
actigraphic measures of sleep/wake activity and energy expenditure prior and subsequent
to CPAP therapy. Analysis of variance (ANOVA) using repeated measures was
performed to identify overall differences between pre-CPAP and one week post-CPAP
and pre-CPAP and one month and post-CPAP sleep activity, wake activity, and 24-hour
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energy expenditure. Sixty-nine subjects were consented, with a total of 35 subjects
completing the study. Data analyses revealed statistically significant mean differences in
sleep activity, wake activity, and energy expenditure from pre-CPAP to post-CPAP at
one week and one month. At baseline, and continuing through one week post-CPAP and
one month post-CPAP, the CPAP compliant group demonstrated less sleep activity, more
wake activity, and expended more energy than the CPAP noncompliant group. This study
concluded that CPAP use is a statistically significant factor affecting sleep activity time,
wake activity time, and energy expenditure. Regardless of CPAP compliance and length
of use, the entire post-CPAP group demonstrated more sleep activity, had less wake
activity, and burned fewer calories. From a clinical perspective, the results of this study
do not support the use of CPAP as a potential weight loss measure in overweight and
obese OSA patients, and emphasize the need for the inclusion of behavioral weight
management and weight loss strategies in an at-risk population for comorbid illnesses.
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CHAPTER I
RESEARCH PROBLEM
Background and Significance

Obstructive sleep apnea (OSA) is a sleep disorder that disproportionately affects
individuals who are overweight or obese. Approximately five percent of the adult
population has OSA, with overweight and obesity a major contributing factor in an
estimated 70% of these cases (Young, Peppard, & Gottlieb, 2002). Diagnostically, OSA
is characterized by repeated upper airway collapse during sleep with subsequent
reduction or cessation of airflow for greater than 10 seconds, occurring at least five times
per hour of sleep. Either complete or partial obstruction of the upper airway and airflow
results in decreased oxygenation and arousal from sleep. The most common cause of
apnea is obesity and associated adipose tissue deposits within the neck, compressing and
narrowing the upper airway, which collapses when the dilator muscle tone is reduced
during sleep (Dempsey, Veasey, Morgan, & O'Donnell, 2010). OSA is often suspected
when snoring, gasping or choking episodes, disrupted sleep, morning headache, and
daytime sleepiness is reported (Guilleminault & Bassiri, 2005). Furthermore, sleep apnea
has been linked to increased risk of hypertension, heart attack, stroke, heart failure,
insulin resistance, depression, fatigue, and sleepiness with related occupational and
driving accidents (Kapur et aI., 1999; Phillips & Kryger, 2005; Punjabi & Beamer, 2005;
Won & Robert, 2007; Young, Peppard, & Gottlieb, 2002).
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Polysomnography (PSG) is the standard diagnostic testing procedure used to
confirm OSA, which measures physiologic parameters during sleep. Traditionally,
treatment of OSA depends on the severity, determined from PSG as a calculated apneahypopnea index (AHI) or respiratory disturbance index (RDI). Conservative treatment is
often the first line of therapy, with weight loss a primary recommendation. Weight loss
has been shown effective in reducing apneic events, particularly in cases where weight
gain coincided with worsening of apnea and related symptoms (Peppard, Young, Palta, &
Skatrud, 2000; Phillips & Kryger, 2005). Lifestyle and behavioral modifications and
sleep hygiene are typical conservative treatment recommendations and often include
weight loss strategies, such as increased physical activity and reduced calorie diets.
According to the Cochrane Database of Systematic Reviews, the success and value of
these first line measures has not been established (Shneerson & Wright, 2007). While
nasal continuous positive airway pressure (CP AP) as an effective form of therapy for
OSA has been well documented, the treatment adherence and compliance as measured
both subjectively and objectively using downloadable compliance meters remains
problematic, despite known cardiovascular, metabolic and quality of life benefits
(Grunstein, 2005; Phillips & Kryger, 2005; Weaver, 2001).
Research has consistently demonstrated the ability of nasal CPAP therapy to
improve overall sleep, daytime fatigue, sleepiness, concentration, attention, and mood in
OSA (Grunstein, 2005; Weaver, 2001). There is evidence that CPAP treatment reduces
hypertension, insulin resistance related to diabetes, inflammatory markers identified in
cardiovascular and cerebrovascular disease, and leptin levels associated with obesity in
OSA (Won & Robert, 2000). These studies fail to translate outcomes to weight loss for
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OSA patients, regardless of favorable changes in obesity-related physiologic parameters
and laboratory variables in OSA patients treated with CPAP.
While the most common cause of OSA is obesity, the effectiveness of CPAP for
weight reduction is not well studied and to date has yielded inconsistent results (Chin et
aI., 1999; Loube, Loube, & Erman, 1997; Noseda, Kempenaers, Kerkhofs, Houben, &
Linkowski, 1996; Peppard et aI., 2000; Redenius, Murphy, O'Neill, AI-Hamwi, & Zallek,
2007). Outcome measures of improved sleep architecture, oxygenation, and sleep
consolidation have been demonstrated during one or two nights of PSG while using
CPAP (Phillips & Kryger, 2005). Other daytime objective and subjective measures of
sleepiness and performance have yielded improvement post-CPAP, yet studies have not
addressed the effectiveness of CP AP, nor the extent of improving overall objective
measures of continuous sleep/wake activity and energy expenditure. There exists
primarily anecdotal and clinical reference to increased energy and activity as a potential
benefit of CPAP treatment. Research incorporating the use of portable actigraphy devices
could address this research gap by objectively, conveniently, and cost-effectively
measuring continuous 24 hour sleep/wake activity and energy expenditure in a patient's
natural environment. Both the Actiwatch® and the Actical®, actigraphy devices, have
the ability to objectively assess 24-hour sleep and wake activity and energy expenditure,
respectively.
Purpose
The purpose of this study was to examine the influence of CP AP therapy on 24hour sleep/wake activity and energy expenditure in overweight and obese OSA adults, as
measured by the Actiwatch® and Actical® devices. Specifically, this research measured
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and tested for differences in 24-hour sleep/wake activity and energy expenditure prior
and subsequent to initiating CPAP therapy.
Conceptual Framework
This research study involved physiologic variables and phenomena that were
derived from the physical/natural science perspective; however, there was not an existing
formal theory, framework, or model that contributed to the structural process
diagrammed in the schematic model (Figure 1). Rather, a synthesis of the available
literature, combined with over 15 years of clinical sleep experience and observation,
guided the framework and provided the theoretical underpinnings. This conceptual
framework, was inductively derived, loosely structured with less specific conceptual
interrelatedness, not directly tied to explicit theory or theories, and offered a general
guidance to the research question and hypotheses.
Variables of significance to this research have been incorporated into the
schematic model and include overweight/obesity (BMI), OSA (polysomnography-AHI),
sleep activity (actigraphy), wake activity (actigraphy), energy expenditure (actigraphy)
and CPAP compliance (internal compliance meter). In this research, the propositions
linking these concepts, as currently diagrammed, include the relationships between
overweight/obesity and OSA, how sleep fragmentation/disruption and daytime
fatigue/sleepiness are associated with OSA, and how (respectively) these concepts link
OSA to increased sleep activity and decreased wake activity, with a decrease in 24-hour
total energy expenditure. The lower half of the diagram illustrates CPAP treatment, with
CPAP compliance affecting sleep consolidation (less sleep fragmentation/disruption),
improving wakefulness (less daytime fatigue/sleepiness), and
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Figure 1. Schematic model illustrating sleep/wake activity and energy expenditure preand post-CPAP in overweight and obese obstructive sleep apnea patients.

5

how (respectively) these concepts negatively correlate CPAP treatment (and level of
compliance) with sleep activity, and positively correlate CPAP therapy with wake
activity and 24-hour total energy expenditure.

Overweight/obesity
Starting at the top of the Figure 1, overweight and obesity have been defined
based on the National Heart Lung and Blood Institute established body mass index (BMI)
guidelines for underweight «18.5), overweight (25-29.9), class 1 obesity (30-34.9), class
2 obesity (35-39.9), and extreme obesity, class 3 (>40) (National Institutes of Health,
1998; National Institutes of Health, National Heart, Lung, and Blood Institute, 2000).

Obstructive sleep apnea
For this study, OSA has been defined using the diagnostic criteria adopted by the
American Academy of Sleep Medicine Task Force (1999), which includes five or more
obstructed breathing events per hour of sleep combined with excessive daytime
sleepiness (not explained by other factors), or at least two of the following (not explained
by other factors): 1) choking or gasping during sleep; 2) recurrent awakenings from
sleep; 3) unrefreshing sleep; 4) daytime fatigue/sleepiness; or 5) impaired concentration.
A diagnosis of OSA includes clinical symptoms confirmed by polysomnographic
findings demonstrating an AHI ~5, using the 2007 AASM scoring guidelines (Iber,
Ancoli-Israel, Chesson, & Quan, 2007).

Obesity and obstructive sleep apnea
As diagrammed, the schematic model demonstrates a link from overweight/obesity
to obstructive sleep apnea, and is supported by evidence that increased weight and
obesity is one of the strongest identifiable risk factors for OSA (Guilleminault & Bassiri,
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2005). While the link between OSA and obesity has been well recognized, the association
is complex and not completely understood (Wolk & Somers, 2006). Collectively, the
cluster of mediating factors related to increased sympathetic activity, inflammation,
endothelial dysfunction, oxidative stress, and hypercoaguability are postulated
mechanisms contributing to the link between OSA and obesity and associated
cardiovascular risk and metabolic dysfunction (Jean-Louis et aI., 2008; Miller &
Cappuccio, 2007; Penev, 2000); however, it has yet to be confirmed that obesity is a
direct cause rather than just a component OSA. These findings support the bi-directional
relationship between overweight/obesity and OSA as diagrammed.

Fragmented/disrupted sleep
Figure 1 illustrates relationships between OSA and fragmented/disrupted sleep and
daytime fatigue/sleepiness, with independent linkages from OSA to fragmented/disrupted
sleep and daytime fatigue/sleepiness. An additional link from fragmented/disrupted sleep
to daytime fatigue and sleepiness is diagrammed, as well. It is the arousals and
awakenings resulting from apneic events that underlie the relationship with
fragmented/disrupted sleep, which is frequently subjectively reported by those with OSA.
Objectively, a polysomnographic arousal is defined by the AASM (Iber et al., 2007) as at
least 3 seconds ofEEG shifting from alpha or theta (wake) waveforms followed by 10
seconds of continuous sleep preceding and following the change; whereas, an awakening
is at least 30 seconds of alpha or theta (wake) waveforms (Iber et aI.).

Daytime fatigue/sleepiness
The most common complaint from those with OSA is daytime fatigue and/or
sleepiness (Guilleminault & Bassiri, 2005; Weaver, 2001; Weaver & George, 2005).
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These terms are conceptually different; however it is not the concern of this study to
objectively operationalize these concepts. These are considered subjective reports most
commonly associated with daytime symptoms of OSA and may range from feeling tired
or drowsy to napping or falling asleep (Guilleminault & Bassiri). The relationship
between OSA and sleep fragmentation and disruption is believed to result in daytime
fatigue and/or sleepiness. It has also been postulated that the direct effects of hypoxemia,
carbon dioxide retention, and sympathetic nervous system activation on visceral obesity,
insulin resistance, and hypercytokinemia lead to daytime fatigue and sleepiness in OSA
patients (Ryan, Taylor, & McNicholas, 2005; V gontzas et aI., 2000).
Sleep and wake activity
Sleep disruption and arousal are included in the constellation of
pathophysiological manifestations of OSA and are usually objectively measured using
polysomnography (American Academy of Sleep Medicine Task Force, 1999). For
purposes of this study, activity refers to gross motor (physical) movements as measured
using an accelerometer (actigraphy) to distinguish 24-hour activity during wake and
sleep. Polysomnographically, sleep activity is measured using electroencephalographic
(EEG) measures and scored based on EEG waveforms, rather than measuring physical
sleep disturbance or movements (Iber et a1.). As measured by actigraphy, increased sleep
activity in those diagnosed with OSA is associated with disruption and arousal during
nighttime sleep resulting in greater total 24-hour sleep time. In terms of
polysomnography, wake activity refers to alpha EEG waveforms consistent with wake. In
this study, decreased wake activity in those diagnosed with OSA refers to less physical
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movement and activity during the day with less total 24-hour wake time (measured by
actigraphy) versus actual EEG wake activity.
In the upper half of the proposed model, OSA depicts a relationship with
decreased wake activity (decreased physical movement with less total 24-hour daytime
wake) and increased daytime fatigue and sleepiness. Studies have revealed subjective
sleepiness in those with OSA as measured by sleepiness scales (Roehrs, Carskadon,
Dement, & Roth, 2005). Likewise, objective sleepiness has been demonstrated in OSA
with controlled maintenance of wakefulness studies (MWT) and multiple sleep latency
tests (MSLT) (Carskadon & Dement, 2005; Roehrs et al.). To date, there have been only
a few studies conducted to assess unrestricted daytime physical activity in OSA patients.
It seems conceptually reasonable that an individual with OSA who experiences sleep

fragmentation and disruption resulting in daytime fatigue and sleepiness would be less
physically active during waking hours, even without empirical data. Jean-Louis et al.
(2008) and Penev (2007), as well as others (Guilleminault & Bassiri, 2005; Vgontzas et
al. 1994; Weaver & George, 2005), have at least hypothesized or provided anecdotal
reference to these phenomena.
Energy expenditure
The sum of activity during sleep and wake can be translated to total daily energy
expenditure, with weight management a balance of energy intake and energy expenditure.
Energy intake is measured by total kilocalories of dietary or nutritional food and
beverage consumed, while energy expended is measured by level of activity, inclusive of
both sleep and wake. The three main components of energy expenditure include basal
metabolic rate (BMR) and resting metabolic rate (RMR), dietary-induced thermogenesis
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(DIT), and physical activity or non-resting energy expenditure (Summerfield, 2001).
While metabolic rate and dietary thermogenesis have been studied in OSA patients for a
single 24-hour duration under controlled metabolic chamber conditions (Major, Series, &
Tremblay, 2007; Ryan, Love, & Buckley, 1995; Stenlof, Grunstein, Hedner, & Sjostrom,
1996), this research is interested in non-resting energy expenditure or physical
movements during sleep and wake, such as fidgeting, random muscle movements,
activities of daily living, exercise, and other movements or activities that can be
measured using actigraphy, over multiple days and translated to energy expenditure.
Research involving OSA and energy expenditure was limited and offered no clear
consensus on whether OSA increases or decreases sleeping EE in OSA patients. Daytime
wake time has been even less well-studied, but anecdotally, is thought to be reduced in
OSA patients as a result of sleepiness and fatigue (Ancoli-Israel, 2005). Overall, these
limited findings do not provide substantive support of energy expenditure changes in
OSA, and further highlight the need for research to address this knowledge gap.

Continuous positive airway pressure
Continuous positive airway pressure (CPAP), when used, leads to less fragmented
sleep, improves variable oxygen desaturation and changes, and decreases cardiovascular
workload and other forms of autonomic nervous system stimulation resulting in favorable
cardiovascular outcomes (Doherty, Kiely, Swan, & McNicholas, 2005; Heitmann et aI.,
2004; Kaneko et aI., 2003; Pepperell et aI., 2002; Stoohs et aI., 1993), less
cerebrovascular disease and better metabolic profiles (Babu, Herdegen, F ogelfeld, Shott,
& Mazzone, 2005; Becker et aI., 2003; Chin et aI., 1999; Harsch et aI., 2003; Harsch et

aI., 2004). Furthermore, CPAP has shown improvements in neuropsychologic and
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cognitive dysfunction (Bardwell, Ancoli-Israel, Berry, & Dimsdale, 2001; Borak et aI.,
1996; Derderian, Bridenbaugh, & Rajagopal, 1998), sleepiness (Yamamoto et aI., 2000),
depression (Means et aI., 2003; Schwartz, Kohler, & Karatinos, 2005), and impaired
quality oflife (Jenkinson, Stradling, & Peterson, 1997; Sin, Mayer, Man, Ghahary, &
Pawluk, 2002).
The lower half of Figure 1 links CP AP compliance with less fragmented sleep and
improved wakefulness, then links CP AP compliance to decreased 24-hour total sleep
activity (measured in minutes via actigraphy) and increased 24-hour total wake activity
(measured in minutes via actigraphy) . The model terminates with an increase in 24-hour
energy expenditure (as measured in kilocalories via actigraphy). As depicted in Figure 1,
it is hypothesized that there is an association between CPAP compliance and sleep
activity, wake activity and energy expenditure. That is, those who are more compliant
with CPAP are more likely to exhibit increased wake activity, decreased sleep activity,
and greater energy expenditure.
Actigraphy
Twenty-four hour energy expenditure, in kilocalories, can be measured using the
Actical® actigraphy device. Likewise, 24-hour sleep and wake activity can be measured,
in minutes, using the Actiwatch® actigraphy device. Hedner et aI. (2004) reported
actigraphy to be a novel approach for assessing sleep-wake activity in OSA patients;
however, only a few studies have used actigraphy to address changes in total 24-hour
sleep/wake activity or non-resting energy expenditure following CP AP treatment.
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Hypotheses
The purpose of this study was to examine the influence ofCPAP on sleep activity,
wake activity, and energy expenditure in overweight (BMI > 25) and obese (BMI > 30)
OSA (AHI ~5) adults. Sleep activity, wake activity and energy expenditure were
measured on a group of overweight and obese individuals prior and subsequent to
initiating CPAP therapy, testing for differences that exist before and after therapy over
time. The framework developed guided this research and addressed each of the following
three hypotheses (hypothesis 1 [HI], hypothesis 2 [H2], hypothesis 3 [H3]):
HI) Subjects will have a significant decrease in 24-hour total sleep activity over time
as a result of using CP AP therapy (measured by the Actiwatch®)
H2) Subjects will have a significant increase in 24-hour total wake activity over time
as a result of using CPAP therapy (measured by the Actiwatch®)
H3) Subjects will have a significant increase in 24-hour total energy expenditure
over time as a result of using CPAP therapy (measured by the Actical®)
Summary
The conceptual framework and corresponding schematic model illustrates a
structural process that is grounded in the literature, based upon findings from prior
studies, and drawn from clinical experience. While illustrated as a structural process, it is
the linking of these concepts, which offered direction to developing the purpose of this
research, formulating hypotheses, and guiding proposed data collection methods. The
literature review and research findings offered sufficient underpinnings to support the
conduct of the proposed study and further suggested additional empirical testing using
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current models that link OSA with obesity, cardiovascular disease and metabolic
dysfunction as a framework for larger prospective studies.
The schematic model provided the concepts and framework to guide this research
in examining sleep activity, wake activity, and total calculated energy expenditure in
overweight and obese OSA patients before and after CPAP treatment using the
Actiwatch® and Actical® devices. Overweight (BMI > 25) and obese (BMI >30) patients
were the targeted population for this study, as their risk of comorbidities are greater than
those non-overweight/obese OSA patients. As research has shown, OSA (AHI ;::5) leads
to disrupted and fragmented sleep, which increases energy expended during sleep. This
sleep disruption results in daytime fatigue and sleepiness, which may reduce 24-hour
total wake time, as determined by physical movement using actigraphy. Because there are
two-thirds more hours of wake time than sleep, decreases in total 24-hour energy
expenditure (caloric expenditure) may be expected. Following CPAP treatment it would
be expected that these OSA patients will experience less sleep disruption and
fragmentation, resulting in less total nighttime sleep, lower energy expenditure during
sleep, less daytime sleepiness and fatigue with increased wake time activity. As stated in
the hypotheses, and following the schematic model, the net loss of energy expenditure
during sleep should be well compensated for during waking hours, and result in an
increase in overall 24-hour energy expenditure following CPAP therapy.
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CHAPTER II
LITERATURE REVIEW
Introduction

This review of the literature will be divided into sections relevant to the concepts
and variables of interest to this study. This chapter will provide an initial overview and
discussion of sleep, obstructive sleep apnea, continuous positive airway pressure and
overweight/obesity. Sleep and wake activity and energy expenditure as the study outcome
variables of interest will be included, followed by a separate sleep-related review of
actigraphy as the primary measurement instrument for this study. A brief introduction
about sleep and the consequences of inadequate sleep and sleep disorders will provide the
foundation to support the importance of sleep for maintenance and promotion of physical
and mental health. OSA will be discussed as one of the most prevalent sleep disorders
and will include a review of OSA pathogenesis, symptoms, diagnosis, health risks and
treatment. A separate section will be devoted to CPAP therapy, as the most commonly
prescribed treatment for OSA, and will address issues pertaining to compliance and
effectiveness. Because OSA is associated with overweight and obesity, this review will
explore the current state of the science as it relates to the link between obesity and OSA,
associated health consequences and weight loss approaches. Furthermore, as the primary
variables of interest to this study, the literature will be examined to identify relationships
between sleep activity, wake activity and energy expenditure in OSA. Lastly, actigraphy,
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as the research instrument used to measure sleep/wake activity and energy expenditure
will be included in the review. Each ofthese areas will be explored in depth, highlighting
the most relevant research findings as it pertains to the present study of 24-hour sleep
activity, wake activity, and energy expenditure in overweight and obese OSA subjects
prior to and following CP AP therapy.
Sleep
Sleep comprises about one-third, or approximately eight hours, of a 24-hour day.
The understanding of sleep has historically evolved from simple subjective observations
to more objective measures of physiologic and behavioral functions, distinguishing
normal sleep from abnormal sleep. Conceptually, sleep has shifted from an intuitive
belief of a passive state of brain and body inactivity, somewhere between wakefulness
and death, to a more highly organized view of sleep as a complex state which is both
qualitatively and quantitatively different from wakefulness, and is initiated and
maintained by specific physiologic and behavioral mechanisms (Dement, 2005).
Sleep involves a balance between physiology (circadian cyclic activity involving
homeostatic regulatory neurologic and hormonal processes) and behavior (sleep-wake
schedules, diet and physical activity, along with environmental, societal and cultural
influences and demands). Any disruption to either physiologic or behavioral processes
may lead to insufficient sleep, sleep disruption and sleep disorders. Individual
consequences associated with sleep disorders result from abnormal or inadequate sleep,
and may include varying degrees of irritability, moodiness, fatigue, tiredness, sleepiness,
somnolence, and lethargy with decreased motivation, attention, memory, and
concentration. (Hodgson, 1991; Vaughn & D'Cruz, 2005). Furthermore, poor sleep and
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sleep disorders have been shown to decrease productivity, reaction time, and attention
span. Evidence has also linked poor sleep and sleep disorders to increased health risks
such as obesity, hypertension, vascular disease, heart disease, stroke, and diabetes
(Vaughn & D'Cruz). Depression, anxiety and substance abuse have also been associated
with inadequate sleep (Lee & Ward, 2005). More recent studies have linked obesity to
inadequate, restricted, or short sleep duration among various age groups and populations
(Gangwisch, Malaspina, Boden-Albala, & Heymsgield, 2005; Hasler et aI., 2004; Patel,
Malhotra, White, Gottlieb, & Hu, 2006; Spiegel, Tasali, Penev, & Van Cauter, 2004;
Taheri, Lin, Austin, Young, & Mignot, 2004;). Additionally, safety issues related to
sleep and sleepiness have been more widely recognized and publicized, primarily the risk
of motor vehicle, commercial, and industrial accidents (Rosekind, 2006).
Sleep is considered a basic need and as critical to health as nutrition and physical
activity (U.S. Department of Health and Human Services [USDHHS], 2003). Even with
substantial sleep knowledge, there exists pervasive illiteracy and ignorance as to the
importance of sleep and the relationship between sleep, sleepiness, wake function, and
performance capacity. This pervasiveness has persisted as a direct result of the failure to
adequately translate existing scientific knowledge linking sleep, sleep disorders, and
health to broad-based research programs, educational initiatives, clinical practice settings,
and public health policy agendas (Institute of Medicine Committee on Sleep Medicine
and Research Board on Health Sciences Policy, 2006; Walsh, Dement, & Dinges, 2005).
Obstructive Sleep Apnea
It has been estimated that 50 to 70 million Americans suffer with sleep disorders

(USDHHS, 2003). Obstructive sleep apnea is just one of more than 70 sleep disorders
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affecting 18 million Americans that disrupt normal sleep architecture and physiology,
resulting in many individual and public health risks and consequences (National Sleep
Foundation, 2002; USDHHS, 2003). These risks and consequences have generally been
poorly translated to public health agendas. More recently, steps have been made toward
this effort with the introduction of objectives related to OSA medical evaluation and
long-term management, and sleep-related motor vehicle safety into the Healthy People
2010 datasets (Healthy People 2010).
Obstructive sleep apnea (OSA) is considered the most common of the sleeprelated breathing disorders. Early descriptions of OSA date back to the 1800s, with a well
known reference to the Pickwickian Syndrome, named for Joe, an obese, excessively
sleepy, snoring boy as described in 1836 by novelist Charles Dickens in the "Posthumous
Papers of the Pickwick Club" (Dement, 2005). It was not until 1965 that OSA was
medically diagnosed using polysomnography in patients with pickwickian syndrome
(Dement), and not until 1970 that OSA was identified in non-obese individuals (Dement).
Pickwickian syndrome is now most often referred to as obesity-hypoventilation syndrome
which is characterized by obesity, snoring, plethoric complexion, cyanosis, peripheral
edema, and right-sided heart failure. While OSA patients may have common features
associated with pickwickian syndrome, the obesity-hypoventilation syndrome is
classified separately and is considered the most severe form of sleep-disordered breathing
(Phillips & Kryger, 2005, Dempsey, Veasey, Morgan, O'Donnell, 2010). Sleepdisordered breathing generally ranges from severe obesity-hypoventilation syndrome to
mild, simple and benign snoring. OSA is the most common of the sleep-related breathing
disorders and is also used interchangeably with obstructive sleep apnea-hypopnea
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syndrome (OSAHS). For purposes of this study, OSA encompasses the spectrum of
obstructive apneas, hypopneas and respiratory disturbance associated with sleep.
Obstructive sleep apnea is an obstruction in upper airway breathing during sleep.
Apneas (and hypopneas) are brief periods of reduced or absent airflow resulting from a
complete or partial upper airway collapse while sleeping. From epidemiologic studies
based on the general population or community cohorts, the incidence of OSA has been
estimated to be between two and four percent of middle-aged men and women, with men
affected more frequently than women (Kripke et aI., 1997; Young et aI., 1993). In more
recent years, an exhaustive epidemiologic review of the literature conducted by Young,
Peppard, and Gottlieb (2002), found that up to five percent of adults in Western countries
are likely to have OSA. While there are numerous studies of infants, children, adolescents
and the elderly with OSA, the scope of this study is limited to adults, ages 18 to 65.
Other factors significant to OSA prevalence rates include menopause, race and ethnicity.
Bixler et aI. (2001) found that after menopause, the prevalence in women equals that of
men. Increased risk and higher prevalence rates of OSA has also been found in African
Americans, Latinos and Asians with craniofacial features identified as the primary
contributing factor (lp et aI., 2001; Scharf et aI., 2004).
Pathogenesis
The pathogenesis of OSA primarily relates to repeated upper airway collapse as a
result of sleep-related neuromuscular compensatory loss and abnormal upper airway
anatomy, either caused by adiposity or craniofacial structure (Nguyen, Yim, & Malhotra,
2007). Structurally, the upper airway consists of the nasopharynx, oropharynx, and
hypopharynx. Collapsibility may be favored based on the size of the upper airway lumen,
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inclusive of the tongue, pharyngeal walls, and adipose tissue. Posterior displacement of
the mandible and inferior placement of the hyoid bone is often implicated in upper airway
collapse (Miles, Weyant, Forrest, & Rockette, 1996). Clinically, these deformities are
referred to as a small chin, overbite, or retrognathia. Schwab et al. (1995) identified the
volume of soft tissue structures surrounding the upper airway as an important OSA
factor, primarily the lateral oropharyngeal structures such as oropharyngeal muscles, the
pharyngeal constrictors, adipose tissue, and lymphoid tissue. Both inflammation and
edema of the soft tissues have been described as both a cause and effect of OSA (Miles et
al.). Additionally, an oropharynx which has a longer anterior to posterior shape, and a
shorter lateral orientation, is more likely to increase predisposition to upper airway
narrowing, resistance, and collapse (Malhotra et al., 2002). Nasal obstruction further
increases negative pharyngeal pressure, airway resistance and collapsibility, and may be
related to deviated nasal septum, mucosal edema and inflammation. Although nasal
obstruction is significant, the effect on OSA is variable and not considered primary
(Pevemagie, Demeyer, & Claeys, 2005). Other causes of upper airway collapse include
involvement of neuromuscular control, lung volume, ventilatory control instability, C02
reserve and loop gain, arousal threshold, and neurotransmitters (Miles et al.); all of which
are all relevant, but the complexity of physiological involvement is beyond the scope of
this study for inclusion.
Overall, the consensus is that OSA results from predisposing anatomical factors
and structural features combined with a decrease in neuromuscular compensation during
sleep. While anatomical structure is critical to evaluating OSA, it does not exclusively
account for the severity of OSA. The primary risk factors for OSA include obesity with
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android-type fat distribution in the neck and abdomen, crowded and narrow oropharynx,
nasal resistance, mandibular deformity and retrognathia, male gender, menopausal
women, and certain ethnicities such as African Americans, Latinos and Asians (Ramar &
Guilleminault, 2007). Other risk factors include middle-age (40 to 65 years old) ,
smoking, alcohol and sedative use, snoring, mouth breathing, supine sleep position, and
conditions causing macroglossia, stroke or neuromuscular disease, congenital
abnormalities affecting craniofacial structure, and polycystic ovarian syndrome (Ramar &
Guilleminault; Young et aI., 2002). A positive family history also increases the risk of
OSA, with genetic predisposition related to obesity and inherited craniofacial features
(Guilleminault & Bassiri, 2005).

Symptoms
Clinically, OSA includes both nighttime and daytime symptoms. Nocturnal
symptoms tend to be more specific to OSA, whereas, daytime symptoms are often a
result of disrupted sleep, regardless of the cause (Guilleminault & Bassiri, 2005;
Dempsey, et aI., 2010). The most common nighttime symptoms or observations of an
OSA patient include a pattern of loud snoring, alternating with brief pauses in breathing,
and followed by gasping or snorting episodes and a brief aWakening. A spouse, family
member, or bed partner usually provides the greatest insight into this characteristic
nighttime pattern associated with OSA, with apneic episodes reported by about 75% of
bed partners (Hoffstein & Szalai, 1993). Most OSA patients are unaware of these
patterns; however, some patients may report varying degrees of restless or disrupted
sleep, diaphoresis, dyspnea or choking sensations, esophageal reflux, nocturia, dry
mouth, drooling, and bruxism (Guilleminault & Bassiri).
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Daytime or wake symptoms of OSA primarily include reports of daytime
sleepiness or fatigue. Sleepiness may range from mild drowsiness and occasional napping
when disengaged and inactive, to more severe episodes of sleep while engaged or
actively eating, talking, or driving. Whether sleepiness is mild, moderate, or severe, there
is usually underlying insufficient sleep associated with OSA respiratory-related arousals
and sleep disturbance. Many may also experience varying degrees of chronic sleep
restriction and/or sleep deprivation. In addition to sleepiness, some patients with OSA
describe changes in dexterity, concentration, attention, memory, andjudgment
(Guilleminault & Bassiri, 2005; Weaver & George, 2005). Personality and mood changes
have been reported, such as aggressiveness, irritability, anxiety, and depression
(Guilleminault & Bassiri). Morning headaches have been described in about half of OSA
patients (Paiva, Farinha, Martins, & Guilleminault, 1997). Decreased libido or impotence
has been reported as well (Guilleminault & Bassiri). OSA has further been associated
with cognitive impairment resulting in decreased work and academic performance,
increased accidents, and diminished quality of life (Weaver & George; Gonsalves, Paiva,
Ramos, & Guilleminault, 2004).
Diagnosis
Diagnosis of OSA is based on symptom presentation and confirmed with
polysomnography (PSG). PSG is the standard outpatient diagnostic procedure conducted
overnight or during a person's usual sleep hours. This testing quantitatively measures
physiologic sleep parameters, inclusive of electroencephalogram (sleep/wake stages),
electrooculogram (eye movements), submental electromyogram (chin movement),
electrocardiogram (heart rate and rhythm), nasal and oral thermocouples/pressure
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transducers (airflow), snore/noise transducers, chest and abdominal bands (respiratory
effort), anterior tibialis electromyogram (leg movements), pulse oximetry (oxygen
saturation) and video recording and audio monitoring. Computer software programs are
utilized for sleep data acquisition and preliminary analysis. Sleep technologists perform
patient hook up with the necessary placement of electrodes and sensors, which is
followed by computer and biologic calibrations and recording. During data acquisition,
the technologists monitor the patient and data closely, both by computer tracings of
recorded physiologic activity and video/audio surveillance. The technologist also initiates
(per physician protocol and order) and titrates continuous positive airway pressure
(CPAP) treatment for those patients diagnosed with sleep apnea or sleep disordered
breathing. A single PSG is usually sufficient for diagnosis (American Thoracic Society &
Medical Section of the American Lung Association, 1989), and if OSA is severe enough,
both diagnosis and treatment with CPAP can be accomplished in one night/stay (McArdle
et ai., 2000). A second night/stay for positive airway titration is indicated for those
patients with more moderate OSA or for those unable to be successfully titrated during
their first night or stay (Wittig et ai., 1984). Using Rechtschaffen & Kales (1968) scale,
sleep data can be scored and analyzed by the sleep technologist, and later reviewed and
interpreted by the board certified sleep specialist. Although Rechtschaffen & Kales has
been the standard for sleep (EEG) scoring for several decades, a new scoring manual for
sleep and sleep-related events has been adopted by the AASM and is required for
accredited sleep centers (Iber, Ancoli-Israel, Chesson, & Quan, 2007). Alternatives to
PSG include portable oximetry and ambulatory home monitoring devices, which offer
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advantages over the laboratory setting, however, have limited diagnostic parameters
(Chesson, Berry, & Pack, 2003).
Level of OSA severity has been somewhat ambiguous and is usually a clinical
judgment derived from PSG and based on a calculated apnea-hypopnea index (AHI) or
respiratory disturbance index (RDI). The AHI or RDI is the most commonly used criteria
to establish a diagnosis of OS A and quantify the severity, and is determined by the total
number of apnea and hypopneas divided by the number of hours asleep (Phillips &
Kryger, 2005). Findings from the Sleep Heart Health Study (SHHS) generated the
greatest consensus about defining apneic and hypopneic events (Sharar et aI., 2001;
Phillips & Kryger). This longitudinal study included over 6000 middle- and older-aged
individuals with cardiovascular disease who underwent in-home portable PSG (Sharar et
aI.). Sharar et aI. defined apneas as an absence up to a 30% of baseline airflow for greater
than 10 seconds, with hypopneas defined as a reduction up to 70% of baseline airflow for
greater than 10 seconds. This definition further required a four percent or more oxygen
desaturation associated with the apneas and hypopneas, but did not include sleep
disturbance or arousal (Phillips & Kryger). These definitions have been more widely
accepted due to cardiovascular predictability and reproducibility of findings (Phillips &
Kryger) and have been adopted by the AASM and outlined in detail in their new scoring
manual (lber, Ancoli-Israel, Chesson & Quan, 2007). The specific criteria for diagnosis
ofOSAHS adopted by the American Academy of Sleep Medicine Task Force (1999)
includes five or more obstructed breathing events per hour of sleep combined with
excessive daytime sleepiness (not explained by other factors), or at least two of the
following (not explained by other factors): 1) choking or gasping during sleep; 2)
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recurrent awakenings from sleep; 3) unrefreshing sleep; 4) daytime fatigue; or 5)
impaired concentration. Severity of apnea has also been a debated issue, with mild OSA
between five and fifteen obstructed breathing events per hour of sleep (AHI ~5 and :S15),
and moderate to severe greater than 15 apneas or hypopneas per hour of sleep (AHI > 15)
mild sleep apnea (Bixler et aI., 2001; Young et aI., 1993 ; Young, Peppard, & Gottlieb,
2002).

Health risks
Health risks associated with OSA have been cited as hypertension (Hu et aI.,
1999; Nieto et aI., 2000; Peppard, Young, Palta, & Skatrud, 2000; Wolk, Shamsuzzaman,
& Somers, 2003), neuropsychologic and cognitive dysfunction (Bedard et aI., 1991;

Engleman et aI., 2000), impotence (Guilleminault & Bassiri, 2005), motor vehicle crashes
(Horstman, Hess, Bassetti, Gugger, & Mathis, 2000; Young, Blustein, Finn, & Palta,
1997), cardiovascular disease (Schafer et aI. 2002; Sharar et aI., 2001), and stroke
(Bassetti & Aldrich, 1999; Bassetti, Aldrich, Chervin, & Quint, 1996). OSA has been
linked endocrine and metabolic disorders, such as type 2 diabetes mellitus (T2DM)
associated with glucose intolerance/insulin resistance (AI-Delaimy, Manson, Willett,
Stampfer, & Hu, 2002; Punjabi, Ahmed, Polotsky, Beamer, & O'Donnell, 2003;
Reichmuth, Austin, Skatrud, & Young, 2005; V gontas, Bixler, & Chrousos, 2005) and
increased leptin levels associated with obesity (Ip et aI., 2001; Spiegel, Tasali, Penev, &
Van Cauter, 2004). Depression (Schroder & O'Hara, 2005; Shepertycky, Banno, &
Kryger, 2005), decreased quality oflife (Baldwin, Griffith, & Nieto, 2001; Weaver,
2000;), and increased health care costs (Kapur et aI., 1999) have been linked to OSA as
well.
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Morbidity and mortality has been reported in large observational studies, with
several studies demonstrating a significantly greater risk for those with moderate to
severe OSA as compared to the general population (Ancoli-Israel et aI., 2001; Kripke et
aI., 1997; Lavie, Lavie, & Herer, 2005; Young, Peppard, & Gottlieb, 2002). Three of the
most commonly referenced longitudinal studies that have demonstrated an association
with OSA and increased cardiovascular morbidities include the Wisconsin Sleep Cohort
Study (Peppard, Young, Palta, & Skatrud), the Nurses' Health Study (Hu et aI., 1999),
and the Sleep Heart Health Study (SHHS) (Nieto et aI., 2000). These studies have all
supported the link between systemic hypertension and OSA. Additionally, the incidence
of pulmonary hypertension has been estimated between 17% and 53% and is most likely
to occur in those with underlying heart or lung disease, or in cases of obesityhypoventilation syndrome (Bady, Achkar, Pascal, Orvoen-Frija, & Laaban, 2000;
Niijima et aI., 1999) . Similarly, the prevalence of coronary artery disease in OSA
patients ranges from 14% to 65% (Andreas, Schulz, Werner, & Kreuzer, 1996), with AHI
shown to be an independent risk factor and predictor for coronary artery and ischemic
heart disease (Peker, Hedner, Kraiczi, & Loth, 2000; Schafer et aI. 1999). As with
coronary artery disease, the prevalence rate of heart failure in OSA patients is quite
variable, from 12 to 54% (Javaheri, 2006; Peppard, Young, Palta, & Skatrud, 2000), and
attributed mainly to large negative intrathoracic pressure increases and hypoxemic
episodes during apneic events (Won & Robert, 2007). Lastly, the SHHS also found a two
to fourfold increased odds of cardiac arrhythmias (bradyarrhythmias, premature beats,
and atrial fibrillation) in patients with an AHI greater than 30 (Mehra et aI., 2006).
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Vascular risks associated with OSA have been explained, at least in part, by
increased sympathetic nervous activity related to numerous arousals during sleep
secondary to obstructed breathing events (Somers & Javaheri, 2005; Dempsey, et aI.,
2010). Collectively, the literature does not agree whether OSA is a cause of
cerebrovascular disease; however, several studies have found intima-media thickness of
the carotid arteries, carotid plaques, and serum inflammatory markers to be increased in
OSA patients (Baguet et aI., 2005; Minoguchi et aI., 2005). Drager et ai. (2005) found
AHI to be an independent predictor of stroke, and the severity of OSA was associated
with increased risk.
Metabolic risks linked to OSA include the complex contribution of both sleep
arousals/fragmentation and increased hypoxia/hypercapnia affecting adipocyte-derived
inflammatory mediators, the sympathetic nervous system, and cortisol secretion at the
hypothalamic-pituitary adrenal axis (Punjabi & Beamer, 2005). Thus, the causal pathway
of metabolic dysfunction and OSA, as reported by Punjabi and Beamer, includes
increases in sympathetic activity, along with changes in hypothalamic-pituitary-adrenal
function, and a predisposition to a pro inflammatory state. Comprehensive reviews of
studies involving OSA and metabolic disorders have shown consistent correlations
between the severity of sleep-related hypoxemia, sleep duration, and glucose intolerance
and insulin resistance, contributing to the risk ofT2DM (Punjabi, Ahmed, Polotsky,
Beamer, & O'Donnell, 2003; Vgontas et aI., 2000). Likewise, a growing body of evidence
has identified apnea-induced dysfunctionalleptin and leptin resistance, further affecting
glucose intolerance, insulin resistance, T2DM, hypertension, and obesity (Coughlin,
Mawdsley, Mugarza, & Calverley, 2004; Shimzu et aI., 2002).
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Sleepiness poses one of the greatest risks to those with OSA, particularly as it
relates to motor vehicle accidents. Sassani et al. (2004) conducted a meta-analysis of
studies from 1980 to 2003, and when combined with National Safety Council data,
findings revealed more than 800,000 drivers were involved in OSA-related motor vehicle
accidents in 2000, costing $15.9 billion and 1400 lives. Drivers with OSA have been
found have higher motor vehicle accident rates at 12% to 31 % versus 3% to 15% in
drivers without OSA (Horstman, Hess, Bassetti, Gugger, & Mathis, 2000). Commercial
long-haul drivers have been estimated to have a higher prevalence of OSA than the
general population, 40% of whom have reported problems with alertness while driving
and 20% of whom have reported dozing at the wheel (Hakkanen & Summala, 2000).

Treatment
To date, continuous positive airway pressure (CPAP) is considered the most
uniformly effective treatment for OSA, and is the only intervention shown to consistently
improve neurobehavioral and cardiovascular morbidities (Veasey et al. 2006).
Unfortunately, as reported by Zozula & Rosen (2001), CPAP is often refused or poorly
tolerated in as many as 25% to 50% of OSA patients. In many cases, conservative
treatment for OSA is offered first line or combined with CPAP therapy. Conservative
treatment focuses on lifestyle and behavioral modifications to improve overall sleep
hygiene and sleep apnea. Such measures include maintaining routine sleep/wake activity
with eight consecutive hours allocated to sleep, altering the sleep environment to control
for comfort, noise and temperature, elevating the head of the bed, lateral or side-lying
sleep position, relieving nasal rhinitis and congestion with intranasal corticosteriods,
smoking cessation, reducing caffeine intake, avoiding alcohol, relaxants and sedative
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medications, increasing physical activity, and avoiding naps (Phillips & Kryger).
Unfortunately, according to Shneerson and Wright (2007) the value of these first line
measures has not been established.
Clinically, weight loss is often a primary recommendation in overweight and
obese patients, and has been shown effective in reducing apneic events, particularly in
cases where weight gain coincided with worsening of apnea and related symptoms
(Phillips & Kryger, 2005). Despite effectiveness in alleviating OSA, weight loss for
overweight and obese patients with moderate to severe OSA usually offers variable
success, both short- and long-term (Shneerson & Wright, 2007). Exercise is often
recommended as a weight loss strategy in addition to reduced calorie diets; although,
little data are available as to the long-term success of such recommendations (Veasey et
aI.,2006). An investigational study conducted by Winslow, Bowden, DiDonato,
McCullough & Day (2010) showed promising results for pharmacologically treating
OSA when combined with lifestyle modification. This study showed statistically
significant weight loss and meaningful improvements in apnea, respiratory-related
arousals, nighttime oxygen levels, subjective sleep quality, and blood pressure (Winslow,
et aI.).
Oral or dental appliances have been used with varying degrees of success in
patients who snore, have mild sleep apnea, or are CPAP intolerant. These appliances are
consistently preferred over CPAP, and have been shown to be more effective than
surgical uvulopalatopharyngoplasty, both short- and long-term (Walker-Engstrom,
Tegelberg, Wilhelmsson, & Ringqvist, 2002). Other surgical intervention for OSA has
included tracheostomy, laser-assisted uvulopalatopharyngoplasty (LAUP), septoplasty,
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oromaxillofacial surgery, and radiofrequency volumetric tissue reduction (somnoplasty)
(Phillips & Kryger). Additionally, bariatric surgery has been applied in morbidly obese
patients with OSA and has been successful in the treatment of OSA caused by obesity
(Buchwald et aI., 2004). While surgical options are important treatment considerations
for OSA patients, it is beyond the scope of reviewed literature for this study. Generally,
as with most forms of OSA treatment, long-term treatment effect and evaluation is
insufficient (Phillips & Kryger). Clearly, studies involving OSA and treatment follow-up
would contribute to identifying better outcome measures for such an at-risk population.
Continuous Positive Airway Pressure
CPAP is considered the primary therapy and treatment of choice for moderate to
severe OSA. CPAP was first described in 1981 (Sullivan et aI., 1981); although, clinical
acceptance and application was not widespread until about 1985 (Grunstein, 2005).
CPAP is a continuous positive flow of air pressure delivered via nasal mask, titrated and
adjusted to a therapeutic level, and measured in centimeters of water pressure ranging
from 5 to 15cm H 2 0. The nasal mask is secured by headgear and is connected by a 6 foot
flexible hose to a lightweight, portable CPAP machine. The CPAP mask is worn during
sleep in order to alleviate snoring and apneic events. While CPAP does not increase
upper airway muscle activity (Strohl & Redline, 1986), endoscopic and upper airway
imaging has confirmed that CP AP does act as an upper airway pneumatic splint,
increasing volume and airway area, reducing pharyngeal wall thickness and edema
(Grunstein). The positive pressure is fixed and delivered continuously throughout
inspiratory and expiratory cycles. Bilevel positive airway pressure therapy is an
alternative to CPAP and is used in select cases to offer independent adjustment of
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inspiratory and expiratory pressures, either to accommodate poor response to CPAP or to
improve pressure tolerance and comfort. Ayas et ai. (2004) conducted a meta-analysis
and found the use of auto-titrating positive pressure machines, versus traditional
supervised PSG titrated and fixed continuous pressure machines (CPAP), has become
more widely used, but studies have shown no improvement in tolerance or compliance
even with modest decreases in pressure. Likewise, a Cochrane review of interventions to
improve use of CP AP was conducted and revealed no clear advantage, or supportive data,
to warrant replacing traditional, less expensive CPAP for more expensive auto-titrating
units in the home (Haniffa, Lasserson, & Smith, 2004).

Compliance
Compliance with CPAP has been referred to in terms of acceptance, prescription,
adherence, tolerance and usage (Grunstein, 2005). The most widely used term is
compliance and will be the preferred term used in this study to indicate objective
measurement of total time wearing CP AP while delivering the established and prescribed
pressure. In recent years, CPAP machines have been manufactured and equipped with a
sophisticated meter to measure actual compliance using a removable card and computer
software to download compliance data (Grunstein). CPAP compliance studies have
demonstrated wide ranges in findings. Some report 58% to 80% of patients refuse CPAP
after initial trial, while others report a 50% CP AP purchase rate. Objective monitoring of
CPAP compliance has revealed about 46% of OSA patients used CPAP 4 hours or more
on at least 70% of the observed nights, with compliance at one month predictive of
compliance at 3 months (Kribbs et aI., 1993; Weaver et aI., 1997). For lack of other data,
this has been cited as the threshold, or minimally accepted value, for compliance. Those
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who do not report symptomatic improvement or are unable to use CPAP at the minimal
criteria are considered unresponsive or noncompliant with CPAP therapy.
The major factors influencing compliance are most frequently associated with
side effects, noise, aesthetics, bed partner intolerance, and inconvenience. Side effects of
CPAP usually lead to poor compliance or discontinued use, and include rhinorrhea, nasal
congestion, nasal/oropharyngeal dryness, epistaxis, skin abrasion/rash, conjunctivitis
related to air leak, chest discomfort, sinus pressure, claustrophobia, and difficulty
exhaling (Grunstein, 2005). There are multiple mask and interface options available to
maximize comfort and fit for patients. Likewise, a ramp feature to allow gradual pressure
increase is available on most CPAP machines, as is a built in humidifier to relieve
dryness. Despite improvements in the size, shape, weight, and noise of CPAP machines,
as well as mask interfaces, humidification and various accessories, compliance remains
an issue. Hoy et aI. (1999) demonstrated that education and positive reinforcement by the
healthcare provider improves compliance; however, the degree to which is necessary is
not clear. Results of a meta-analysis confirmed that patients who have more severe
symptoms and are sleepier at baseline have greater objective CPAP usage (Patel et aI.,
2003).
Health benefits
CPAP, when used, leads to less fragmented sleep, improves variable oxygen
desaturation and changes and decreases cardiovascular workload and other forms of
autonomic nervous system stimulation. CPAP has also been shown to improve leptin and
ghrelin levels, central obesity, and insulin sensitivity (Babu, Herdegen, Fogelfeld, Shott,
& Mazzone, 2005; Chin et aI., 1999; Harsch et aI., 2003; Harsch et aI., 2004).
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Furthermore, findings suggest CP AP can reverse or reduce the risks associated with
OSA, including mortality (Lavie, Lavie, & Herer, 2005; Marti et aI., 2002), hypertension
(Becker et aI., 2003; Heitmann et aI., 2004; Pepperell et aI., 2002;), cardiovascular
disease (Doherty, Kiely, Swan, & McNicholas, 2005; Kaneko et aI., 2003; Stoohs et aI.,
1993), cerebrovascular disease (Martinez-Garcia et aI., 2009), neuropsychologic and
cognitive dysfunction (Bardwell, Ancoli-Israel, Berry, & Dimsdale, 2001; Borak et aI.,
1996; Derderian, Bridenbaugh, & Rajagopal, 1998), sleepiness (Yamamoto et aI., 2000),
depression (Means et aI., 2003; Schwartz, Kohler, & Karatinos, 2005), impaired quality
oflife (Jenkinson, Stradling, & Peterson, 1997; Sin, Mayer, Man, Ghahary, & Pawluk,
2002), impotence (Karacan & Karatas, 1995), car crashes, and health care costs (Findley
& Suratt, 2001; Sassani et aI., 2004). It has been estimated that treating all drivers who

have OSA with CPAP would save 900 lives and yield a net savings of $11 million per
year (Sassani et aI.).
Although the benefits of nasal CPAP as an effective form of therapy for OSA has
been well documented, treatment adherence and compliance remains problematic, despite
known cardiovascular, metabolic, and quality of life benefits. While the data suggests
favorable effects of CP AP, many questions and gaps remain, which include compliance,
responsiveness to therapy, and long-term benefits (Caples, Gami, & Somers, 2005).
According to Grunstein (2005) and Basner (2007), true CPAP compliance remains
unknown, as most follow-up studies have biases related to selected patient populations
and sampling. To address this need, the current and ongoing multi-center National Heart
Lung and Blood Institute (NHLBI)-funded Apnea Positive Pressure Long-term Efficacy
Study (APPLES) has been developed and designed to evaluate the long-term
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effectiveness and benefits of CPAP in relation to improving neurocognitive function,
mood, sleepiness, and quality of life (Kushida, 2007). Likewise, efforts from the Centers
for Disease Control and Healthy People 2010 epidemiologic and surveillance studies may
provide future insight into follow-up, long-term management and outcomes of CPAP
therapy in patients with OSA. Additional research addressing responsiveness to therapy
in terms of sleep and wake activity and CPAP compliance would offer contribution
toward filling the gaps in the current body of knowledge and state of sleep science.
Overweight and Obesity
Obesity is one of the strongest identifiable risk factors for OSA. It has been
estimated that 40% of all obese patients have OSA, and 70% of all patients with OSA are
obese, with the risk of OSA in obese individuals ten times greater than that of the general
population (V gontzas et al. 1994). Although not completely understood whether a cause
or effect, cross-sectional studies have endorsed the relationship between obesity and OSA
to be primarily associated with increased body mass index, central obesity, upper airway
fat distribution, and large neck size (Tasali & Van Cauter, 2002; Tung, 2005; Young,
Peppard, & Gottlieb, 2002).
Overweight is considered weight in excess of the average for a given height;
whereas, obesity is defined as an excess of body fat (Stunkard & Wadden, 1993). Obesity
can be classified by level of fatness (total fat percentage of body weight), distribution of
fat (location of stored fat), and body weight (Summerfield, 2001). The most commonly
used measure to classify body weight is body mass index (BMI). BMI can be calculated
using the formula: weight in kilograms divided by height in meters squared. The NHLBI
established guidelines based on BMI for underweight «18.5), overweight (25-29.9),
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class 1 obesity (30-34.9), class 2 obesity (35-39.9), and extreme obesity, class 3 (>40)
(National Institutes of Health, 1998; National Institutes of Health, 2000).
Obesity trends from the U.S. Centers for Disease Control and Prevention (CDC),
Behavioral Risk Factor Surveillance System (2007) graphically demonstrate dramatic
increases in the prevalence of obesity (BMI

~30)

in the United States from 1985 to 2006

(U.S. Department of Health and Human Services & Centers for Disease Control and
Prevention, 2007). Of the states participating in the BRFSS in 1990, 10 had a prevalence
of obesity less than 10% and no states had prevalence equal to or greater than 15% (U.S.
Department of Health and Human Services & Centers for Disease Control and
Prevention). By 1998, no state had prevalence less than 10%, seven states had a
prevalence of obesity between 20 and 24%, and no state had prevalence equal to or
greater than 25% (U.S. Department of Health and Human Services & Centers for Disease
Control and Prevention). In 2006, only four states had a prevalence of obesity less than
20%,22 states had a prevalence rate equal to or greater than 25%, and 2 states
(Mississippi and West Virginia) had equal to or greater than 30% (U.S. Department of
Health and Human Services & Centers for Disease Control and Prevention). These
alarming figures have continued to rise, and even more recent data collected from 2009
has shown only one state (Colorado) and the District of Columbia to have had a
prevalence of obesity less than 20%. (U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, 2011). According to National Health and
Nutrition Examination survey (NHANES) data from 2003-2004, 66.3% of adults age 20
and older are overweight or obese, and 32% are obese (National Center for Health
Statistics, 2007). This same data reveals the prevalence of overweight in adolescents age
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12-19 to be 17%, and children age 6-11 is 19% (National Center for Health Statistics).
While the adult population is of interest to this study, overweight and obesity in children
and adolescents have current, as well as future adult health implications. Overweight and
obesity poses a major public impact in terms of health, healthcare costs, and quality of
life.
Specific factors implicated in the obesity epidemic include activity level and
physical fitness, diet and nutritional intake, drug and alcohol use, and smoking
(Summerfield, 2001). Health risk factors are associated with the level of overweight or
obesity (higher BMI), age of onset and duration (younger and longer), location of fat
storage (central or visceral), and race-ethnicity (African American and Hispanic)
(National Institutes Of Health, 1998). Obesity is directly linked to cardiovascular disease
and hypertension, (Wolk, Shamsuzzaman, & Somers, 2003; Wolk & Somers, 2006). In
addition, dyslipidemia, T2DM, cancer, osteoarthritis, pregnancy complications and sleep
apnea are associated with obesity (Caterson et aI, .2004; Flegal, Graubard, Williamson, &
Gail, 2005; Summerfield, 2001; Wilson, D'Agostino, Sullivan, Parise, & Kannel, 2002).
As previously discussed, findings have shown OSA to be not only a health risk factor
associated with obesity, but an independent contributing factor to many of these same
comorbidities (Caterson et aI, .2004; Dyken, Ali, Raman, & Eppen, 2007; Mullis et aI.,
2004). Furthermore, there is supportive evidence that metabolic and endocrine changes
which promote obesity and diabetes may be a result of not only sleep disruption and
arousal caused by OSA, but sleep loss and overall short sleep duration, as well (Chaput et
aI. 2007; Hasler et aI., 2004; Spiegel, Leproult, & Van Cauter, 1999; Taheri, Lin, Austin,
Young, & Mignot, 2004).
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Obesity and obstructive sleep apnea
Many studies have identified the relationship between obesity and OSA, with
cross-sectional studies demonstrating increased body weight parallels the risk and
severity of OSA (Young, Peppard, & Gottlieb, 2002). Prospective population-based
studies have shown that a 10% weight gain resulted in a sixfold increase in developing
OSA, while a 10% weight loss decreased the AHI by 26% (Peppard, Young, Palta, &
Skatrud, 2000). As reported by Young et aI. (2002), the Wisconsin Sleep Cohort study,
and the Cleveland Family Study revealed findings consistent with excess body weight
and central obesity to be a significant predictor of OSA and increased AHI . Specifically,
a BMI of>28 kg/m 2 has been shown to increase the risk of OSA in both middle-aged
men and women (Ancoli-Israel et aI., 2001). Although the prevalence of OS A associated
with central obesity continues to increase with age (Kripke et aI., 1997), the link between
obesity and OSA has been shown to decline for both genders after age 50 (Ancoli-Israel
et aI.; Young et al; Young, Peppard, & Gottlieb).

Weight loss approaches
When considering weight loss approaches as treatment for obese and overweight
OSA subjects, CP AP has been shown to decrease total body fat and central adiposity in
only a few studies (Chin et aI., 1999; Loube, Loube, & Erman, 1997; Noseda,
Kempenaers, Kerkhofs, Houben, & Linkowski, 1996). Interestingly, Peppard, Young,
Palta, and Skatrud (2000) found newly diagnosed patients with OSA have a greater
increase in weight the year prior to diagnosis, and patients who comply with CPAP
tended to gain weight. Redenius, Murphy, O'Neill, AI-Hamwi, and Zallek (2007) also
noted increased BMI in women after 1 year of CP AP, with no BMI change in controls.
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Buchwald et ai. (2004) conducted a systematic review and meta-analysis ofbariatric
surgery and indicated the impact of surgical weight loss, particularly gastric bypass, on
OSA and AHI demonstrated favorable results. Grunstein, Stenlof, Hedner, Peltonen,
Karason, and Sjostrom (2007) found improvement in the incidence of sleep apnea
symptoms, diabetes, and hypertriglyceridemia two years following bariatric surgery. A
study examining three non-surgical treatments for OSA (CPAP, oral appliance, and
weight loss) found CPAP resulted in the most improvement in physiologic, symptomatic
and quality oflife measures, followed by oral appliance (Lam et aI., 2007). In this study,
weight loss demonstrated improved sleep parameters, but weight control was not
uniformly effective (Lam et aI.). Kajaste, Brander, Telakivi, Patinen, and Mustajoki
(2004) evaluated a cognitive-behavioral weight reduction program in the treatment of
OSA, both with and without CPAP, and found weight loss was achieved with this
program; however, adding CPAP did not offer any greater weight loss. Despite routine
recommendations about the importance of weight loss in the treatment of OSA, there is
very little documented clinical intervention. As reported by Peppard et aI., the Wisconsin
Sleep Cohort Study found that further increases in weight and AHI would result if
therapy directed toward overweight and obesity was neglected.
Health consequences
Obesity has been cited as responsible for between 300,000 and 400,000 deaths per
year in the United States (Mokdad et aI., 2004; USDHHS, 2001; Allison et aI., 1999).
Most ofthese deaths are attributable to coronary artery disease, hypertension, and T2DM
(Mokdad et aI.; Allison et aI., 1999). It has been suggested that this number may be, at
least in part, due to the prevalence of OSA in 30% of adults with a BMI > 30kg/m2 and

37

50% of adults with a BMI >40kg/m 2 (Resta et aI., 2001). Both direct and indirect costs of
obesity have been estimated at $117 billion per year related to medical and healthcare
costs and associated comorbidities (USDHHS, 2001; Wolf & Colditz, 1998; Wolf, 1998).
Given the present obesity trend and the strong relationship between obesity and
OSA, health and healthcare costs can only be expected to rise exponentially without
prioritizing public and individual healthy weight management and weight loss
interventions at the national, state and local levels (See, Mensah, & Olopade, 2006).
Programs and initiatives focusing on nutrition and physical activity have been developed
with federal, state and local funding; however, sleep, as an important one-third of life and
health, has been absent from these initiatives. Research addressing the OSA population,
70% of whom are estimated to be overweight or obese, has relevance and importance to
improving both individual and public health outcomes.
Sleep Activity, Wake Activity, and Energy Expenditure
The sum of activity during sleep and wake can be translated to total daily energy
expenditure, with weight management a balance of energy intake and energy expenditure.
Energy intake is measured by total kilocalories of dietary or nutritional food and
beverage consumed, while energy expended is measured by level of activity, inclusive of
both sleep and wake. A kilocalorie (kcal) is determined by the amount of heat required to
raise the temperature of 1 kilogram of water 1 degree Celcius, which is measured using a
bomb calorimeter.
The 3 main components of energy expenditure include basal metabolic rate
(BMR) and resting metabolic rate (RMR), dietary-induced thermogenesis (DIT), and
physical activity or non-resting energy expenditure (Summerfield, 2001). BMR is usually
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slightly lower than RMR, which can be more practically measured any time of the day
and under less stringent conditions. Simplified, BMR is the total oxygen consumption of
the active tissues in the body. Metabolic rate is the calorie expenditure required to
support the body's cellular activity. As with measuring kcals, metabolic rates are
determined by using direct calorimetry or indirect calorimetry (Summerfield). Direct
calorimetry involves the use of a controlled chamber with walls lined with water to
measure heat production and energy expenditure by temperature changes in water lining
the walls of the chamber. While this method is more accurate, indirect calorimetry
(spirometry) is often more practical, but still involves a face mask, hood or mouthpiece to
measure inhaled oxygen and produced carbon dioxide using the respiratory quotient for
calorie expenditure and estimated energy expenditure (Henning, Lofgren, & Sjostrom,
1996). RMR is affected by many factors, including body size, thyroid hormone,
nutritional status, gender, age, race, and heredity (Summerfield, 2001). Physical activity
involves energy expenditure, but changes in RMR are debated by researchers. The type,
intensity, and duration of physical activity, as well as age, gender and type and quantity
of food ingested following the activity may all have some varied level of influence on
RMR. Another factor related to energy expenditure is diet-induce thermogenesis (DIT),
which is the production of heat by the body in response to eating, contributing to a rise in
RMR. DIT is otherwise known as the thermic effect of food and involves the energy
expended associated with dietary ingestion, digestion, absorption, and transport of
nutrients, as well as increased sympathetic activity and heat production by brown adipose
tissue (BAT) resulting from ingested calories. Lastly, non-resting energy expenditure or
activities such as fidgeting, random muscle movements, activities of daily living, exercise
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and other physical activities are included as the final component to measuring energy
expenditure.
A more practical measurement of energy expenditure for activity includes doublelabeled water method and heart rate monitoring (Ravussin & Rising, 1992; Summerfield).
The first of which estimates carbon dioxide production from isotopes eliminated in the
urine (Ravussin & Rising), with the latter using heart rate to estimate oxygen
consumption and the amount of kcals expended. Metabolic equivalent tasks (MET) have
been developed to estimate calorie cost of various physical activities and energy
expenditure (Ainsworth et aI., 1993). Regardless of how measured, it is ultimately the
difference between energy in and energy out that leads to weight gain, loss, and
maintenance.
Overweight and obese individuals have higher absolute RMRs, potentially
dysfunctional BAT, and are less physically active than those with ideal body weight. As
it relates to OSA, it has been shown that energy expenditure in OSA patients is greater
during sleep than those without OSA (Bonnet, Berry, & Arandel, 1991; Stenlof,
Grunstein, Hedner, & Sjostrom, 1996). This is speculated to be due to airway obstruction
and hypoxemialhypercarbia resulting in increased arousals and disruption during sleep,
along with increased sympathetic nervous system activity. Waking activity is less well
studied, but also speculated to have the potential to be reduced in OSA patients due to
daytime sleepiness and fatigue associated with OSA (Ancoli-Israel, 2005). Several
studies have evaluated weight gain in OSA patients prior to and following diagnosis, and
have evaluated weight loss interventions with and without various treatment modalities
(CPAP, low calorie diets, behavioral and surgical intervention) (Buchwald et aI., 2004;
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Kajaste et aI., 2004; Lam et aI., 2007; Peppard et aI., 2000; Redenius et aI., 2007; Young
et aI., 2002) . These studies confirm the relationship between weight gain, overweight,
and obesity and the development of OSA. They also endorse that weight loss, regardless
of the intervention, decreases the severity of apneas and hypopneas and can improve
OSA symptoms. Albeit limited, there is conflicting evidence regarding the ability of
CPAP to reduce weight in OSA patients, with some evidence of weight gain.
Two studies were found that addressed energy expenditure in OSA patients. A
study by Ryan, Love, and Buckley (1995) identified a lack of evidence regarding the
effects of sleep disorders on energy expenditure. Their research was interested in
determining whether resting energy expenditure (REE) during wake and dietary
thermogenesis were reduced in OSA patients. Energy expenditure was measured using
indirect calorimetry in a metabolic cart and canopy system, further expressed in
metabolic body size (Ryan et aI.). Patients with OSA had increased REE compared to
matched-weight controls; however, once correction was made for lean body mass, both
REE and dietary thermogenesis failed to show a difference between groups (Ryan et aI.).
Measurements were repeated following CPAP therapy in the OSA patients, but again, did
not reveal any differences in resting energy expenditure or dietary thermogenesis.
Obesity in OSA patients was found to be lifestyle and diet-induced, and related to
reduced waking energy expenditure, rather than hypothalamic mechanisms (Ryan et aI.).
This would be consistent with speculation that OSA patients are more likely to gain
weight prior to diagnoses and fail to lose weight following CPAP treatment, despite
improvement in the hypothalamic-pituitary adrenal axis (Ancoli-Israel, 2005; Traviss,
Barr, Fleming, & Ryan, 2002).
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Stenlof, Gruenstein and Hedner (1996) examined 24-hour energy expenditure
(EE) in 5 male patients with OSA and 6 control snoring sUbjects. Three months following
CPAP treatment in the OSA patients, 24-hour EE was again conducted. In order to
measure EE, patients were studied using indirect calorimetry in a controlled metabolic
chamber equipped like a hotel room. Each patient was studied for a single 24-hour
period, with those using CPAP studied an additional 24-hour period. OSA patients had
higher sleep EE and 24-hour EE than the snorers. It was concluded that OSA increases
sleep EE higher than quiet wakefulness, and treatment with CPAP decreases sleep EE by
an average of 16% (Stenlof et al.). The researchers explained 3 possible mechanisms
which could account for increased sleeping EE in OSA patients. These explanations
included increased frequency of arousals during sleep due to apneic events, increased
breathing efforts against upper airway occlusion, and increased sympathetic activity of
the sympathetic nervous system (Stenlof et al.). There were no observed changes in
daytime EE; although the authors indicated the study was limited due to the controlled
environment and restriction of patient wake activity required for indirect calorimetry
(Stenlof et al.). Stenlof et al. stated that ambulatory measures ofEE in OSA patients have
yet to be performed, and findings of increased sleep EE in OSA patients have
implications for energy and weight management. They further suggested that additional
study of OSA patients should be conducted in an unrestricted and natural environment,
which may offer utility in the development of weight loss strategies in this population
(Stenlof et al.). Despite clinically relevant findings, both studies by Stenlof et al. and
Ryan et al. were limited in the number of patients as well as the ability to study these
patients in a 24-hour uncontrolled and natural setting.
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Actigraphy
When evaluating sleep and wake activity, actigraphs, actimeters, accelerometers,
or activity monitors have been utilized as devices to record 24-hour movement or
activity. For this study, actigraphy is the preferred term used to encompass all forms of
this device in this review. In sleep, actigraphs have been most extensively used in the
study of circadian rhythms, and were first used to differentiate sleep from wake in the
early 1970's (Ancoli-Israel, 2005). With advances in technology, actigraphy has been
applied to the evaluation of insomnia, circadian rhythm disorders, sleep-related breathing
disorders, response to therapy, and sleep patterns in special populations (Morgenthaler et
aI., 2007). In these instances, actigraphy has offered objective measurement of sleep
duration and circadian patterns of sleep. Actigraphy, however, does not replace
electroencephalogram-defined sleep or standard PSG; nor does it account for subjective
measures of sleep experiences (Morgenthaler et al.). The device is simply meant to
measure movement of a limb and is usually worn on the wrist or ankle. Despite the
simplicity, actigraphy is highly sensitive and involves complex and sophisticated
algorithms for estimating sleep and wake activity (Ancoli-Israel). The simple basis of this
device is that it detects decreased movement or inactivity when sleeping and increased
movement or activity while awake. The complex algorithms for scoring data have
varying degrees of accuracy depending on the specific device, with some offering greater
ability to distinguish wake, sleep, sleep onset, awakenings during sleep and total sleep
time (Ancoli-Israel). A number of computer software programs are available with
actigraphy devices and offer packages for editing and scoring of activity and sleep/wake
data; however, most are used in combination with a manual activity or actigraph log to
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aid in editing specific to time in bed, out of bed, unusual activity during the day or device
removal (Ancoli-Israel).
Actigraphy has been reported to be best at estimating total sleep time, but
becomes less accurate with disturbed sleep (Elbaz, Roue, Lofaso, & Quera, 2002).
Additionally, several studies have revealed actigraphy may underestimate wake (Bedner
et ai. 2004; Lichenstein et aI., 2006), and a recent epidemiologic study also has reported
the potential for overestimating sleep (Lauderdale et aI., 2006). Regardless, most studies
have consistently shown actigraphy to be a valid assessment of sleep patterns with
significant correlation to PSG in measuring total sleep time (Matsumoto et ai. 1998;
Bedner et aI.; Vallieres & Morin, 2003). Advantages include its cost-effectiveness and
ability to record sleep and wake activity in a natural environment, during both night and
day for continuous 24 hour and extended periods oftime (Ancoli-Israel).
In 2007, the American Academy of Sleep Medicine conducted an evidence-based
review of the use of actigraphy in the clinical assessment and management of sleep and
sleep disorders. In this review, actigraphy was used to describe a method of measuring
increased wake time after sleep onset and "sleep pattern", defined as "the circadian
pattern of sleep and wakefulness over multiple sleep cycles" (Morgenthaler et aI., 2007,
p. 521). Recommendations for the use of actigraphy in clinical practice involved the
following 3 areas: 1) actigraphy in the evaluation of sleep disorders; 2) actigraphy in
assessing the response to therapy of sleep disorders; and 3) actigraphy in special
populations and special situations (Morgenthaler et aI.). Practice parameters were
developed based on evidence collected from 108 studies reviewed. Approximately 38 of
these studies did not compare actigraphy to a reference standard, while 70 of the studies
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compared actigraphy to a standard, such as PSG, phase markers, sleep logs/diaries or
subjective estimates of sleep quality (Morgenthaler et aL). Studies have been conducted
using actigraphy to determine total sleep time of healthy patients, patients with OSA, and
infants, as compared to PSG, and found that there was a 90%,84% and 84% agreement
in the two measures, respectively (Hedner et aL 2004). Studies have also used actigraphy
in instances where PSG was not available to estimate total sleep time in OSA patients, in
addition to using combined monitoring of respiratory events and actigraphy to assess the
severity of OSA. Lastly, actigraphy has been shown to be useful in determining outcomes
and treatment response for circadian rhythm disorders Get lag and shift work) and
insomnia (Morgenthaler et aL).
While both OSA and treatment response were addressed using actigraphy, there
were only a few studies published that utilized actigraphy to evaluate response to CPAP
treatment in OSA patients (Gadnoadoux, Nguyen, Rakotonanahary, Vidal, & Fleury,
2004; Albert-Tulkens et aI., 1987). Gadnoadoux et aL were interested in correlating total
sleep time (TST) in OSA patients using CPAP as measured by actigraphy, as compared
to PSG, and found highly correlated sleep times with the exception of overestimations
and underestimations in 3 out of26 patients. Albert-Tulkens et aL used wrist actigraphy
to measure a movement and fragmentation index during sleep, and demonstrated higher
indices of movement and fragmentation in patients with sleep apnea, with decreased
indices following treatment. Neither ofthese studies (Gadnoadoux et al; Albert-Tulkens)
addressed changes in total 24-hour sleep/wake activity after CPAP treatment. More
recent publications by West, Kohler, Nicoll, & Stradling (2009) and Otake et aL (2010)
studied the effect of CPAP on sleep/wake activity using actigraphy. West et aL studied
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36 men with OSA and found there were no significant differences in activity levels one
week before the initiation of CPAP as compared to one week after CPAP therapy. Otake
et aI. confirmed agreement between PSG and actigraphy sleep/wake data, and further
determined subjects treated after one month of CPAP had significantly less activity
levels/movement than prior to CPAP. No additional research was found to support or
negate the findings from these studies. In fact, more clinical and anecdotal evidence
demonstrates otherwise.
It has been concluded that additional research using actigraphy should be

considered to further expand the value in clinical settings (Morgenthaler et aI., 2007;
Ancoli-Israel, 2005; West et aI., 2009; Otake et aI., 2010). Because of advantages over
subjective sleep diaries or logs, actigraphy has been cited as an important tool for use in
follow-up studies to examine treatment efficacy and outcome (Ancoli-Israel). This is
most relevant to this research study and purpose, as it relates to using actigraphy in
assessing treatment outcome in sleep disorders; specifically, to evaluate the response of
OSA patients to CPAP therapy, not in terms of determining respiratory events or isolating
only sleep activity, but the assessment of total 24-hour sleep and wake activity combined
with measures of CP AP compliance and energy expenditure.
Because assessing total energy expenditure is important to this study purpose, an
actigraphy device that measures sleep activity, wake activity, and calculated total energy
expenditure would be of primary interest. Respironics® markets both the Actiwatch®
and Actical® device, which offered utility as measurement tools for this study. While the
Actiwatch® has been used extensively in sleep research to measure sleep and wake
activity, the Actical® has not been used to measure activity and energy expenditure in
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sleep, OSA, or CPAP patients. The intended use ofthe Actical®, as reported in
premarket summary, is to serve as "a compact, lightweight, waist, wrist, or ankle worn
activity monitor that may be used to assess human gross motor activity, caloric
expenditure and estimates of energy expenditure based on motor activity in any instance
where quantifiable analysis of physical motion is desirable" (Respironics, Inc®, 2006,
pp. 1-2). To date, the Actical® has been used in a variety of metabolic, behavioral,
activity, and physical exercise research, dating back to 1998, and has been validated in
adult, child and adolescent populations (Mini Mitter®, 2003). The device uses an
accelerometer to provide measurement of acceleration in activity counts and calculation
of activity energy (calorie) expenditure. Sleep software programs are available with the
Actiwatch®, and when combined with the Actical®, these are ideal devices to measure
variables of sleep and wake activity and energy (calorie) expenditure for this study.
Summary
The literature identifies sleep to have restorative powers to improve wakefulness,
increase attention and memory, and promote higher level mental and physical functioning
and performance (Carskadon & Dement, 2005). Despite substantial sleep knowledge,
there exists a pervasive failure to disseminate and translate existing knowledge and
educate healthcare professionals and the public about sleep, sleep disorders and health
(Walsh et al.; Institute of Medicine Committee on Sleep Medicine and Research Board on
Health Sciences Policy, 2006). As a result, the numbers ofthose suffering with sleep
disorders continues to grow, currently estimated at 50 to 70 million Americans, 18
million of whom are estimated to have obstructive sleep apnea (U.S. Department of
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Health And Human Services, National Institutes of Health, National Heart, Lung, and
Blood Institute, & National Center on Sleep Disorders Research, 2003).
OSA disrupts normal sleep architecture and physiology, resulting in many
individual and public health risks (National Sleep Foundation, 2002; U.S. Department of
Health And Human Services, National Institutes of Health, National Heart, Lung, and
Blood Institute, & National Center on Sleep Disorders Research). Such risks include
hypertension, neuropsychologic and cognitive dysfunction, impotence, sleepiness related
motor vehicle crashes, cardiovascular disease, and stroke (Phillips & Kryger, 2005;
Young, Peppard, & Gottlieb, 2002). Additional OSA risks include T2DM associated with
glucose intolerance/insulin resistance and metabolic syndrome, and increased leptin
levels associated with obesity (Punjabi & Beamer, 2005). Sleepiness, depression,
decreased quality oflife, and increased health care costs (Kapur et aI., 1999; Won &
Robert, 2007) have been linked to OSA as well. Clearly, OSA patients are an at-risk
population.
Although the benefits of nasal CPAP as an effective form of therapy for OSA has
been well documented, treatment adherence and compliance remains problematic, despite
known cardiovascular, metabolic and quality oflife benefits (Basner, 2007; Grunstein,
2005; Phillips & Kryger, 2005). While the data suggests favorable effects ofCPAP,
many questions and gaps remain including compliance, responsiveness to therapy and
long-term benefits. Additional research addressing responsiveness to therapy in terms of
sleep and wake activity and CP AP compliance would offer contribution toward filling the
gaps in the current body of knowledge and state of sleep science.
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As OSA relates to overweight and obesity, there is a direct link to cardiovascular
disease, hypertension, dyslipidemia, T2DM, cancer, osteoarthritis, pregnancy
complications, and sleep apnea (Won & Robert, 2007; Leinum, Dopp, & Morgan, 2009).
Findings have shown OSA to not only be a health risk factor associated with obesity, but
an independent contributing factor to many of these same comorbidities (Dyken, Ali,
Raman, & Eppen, 2007; Leinum et al). Additionally, there is supportive evidence that
metabolic and endocrine changes which promote obesity and diabetes may be a result of
not only sleep disruption and arousal caused by OSA, but sleep loss and overall short
sleep duration, as well (Spiegel, Leproult, & Van Cauter, 1999; Hayes, Xu, Babineau,
Patel, 2011). Given the present obesity trend and the strong relationship between obesity
and

~SA,

health and healthcare costs can only be expected to rise exponentially without

prioritizing public and individual healthy weight management and weight loss
interventions. Research addressing the OSA population, 70% of whom are estimated to
be obese, has such relevance and importance to both individual and public health.
The Actiwatch® and Actical® are ideal devices, and in combination have the
ability to measure sleep activity, wake activity and calculated total energy expenditure,
respectively. To date, the Actical® has been used in a variety of metabolic, behavioral,
activity and physical exercise research, and has been validated in adult, child and
adolescent populations (Mini Mitter®, 2003). The device uses an accelerometer to
measure both frequency and intensity of movement with activity counts and calculation
of activity energy (calorie) expenditure. A software program is available for use with the
Actiwatch® to download variables of sleep and wake activity. Likewise the Actical®,
has a software program to download acquired data and determine energy (calorie)
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expenditure (Mini Mitter). Actigraphy, using the Actical® device, to evaluate EE in OSA
patients has yet to be performed, but has implications for measuring energy expenditure
and weight management in OSA patients. Combining the Actiwatch® and Actical® to
study OSA patients in an unrestricted and natural environment, both prior to and
following CPAP treatment, would contribute to measuring treatment efficacy, and
provide data potentially useful to developing weight loss strategies in this population
(Stenlof et al.).
Overweight and obesity is a major factor in OSA, contributing not only to its
pathogenesis, but complicating its management and contributing to related comorbidities.
Clinically, addressing obesity treatment presents challenges to OSA patients and health
care providers, with little evidence supporting CPAP as a significant weight loss measure.
This study aims to contribute to the current state of sleep science by addressing an
important knowledge gap in the treatment of overweight and obese OSA patients;
specifically, to assess the effect of CPAP treatment on 24-hour total sleep activity, wake
activity and energy expenditure as measured in a patient's routine and usual environment,
while accounting for CP AP compliance.
Current recommendations for research in OSA patients have highlighted the need
for treatment outcome studies (Institute of Medicine Committee on Sleep Medicine and
Research Board on Health Sciences Policy, 2006; U.S. Department of Health and Human
Services, National Institutes of Health, National Heart, Lung, and Blood Institute, &
National Center on Sleep Disorders Research, 2003). While there is evidence supporting
favorable effects and improvement in sleepiness, quality oflife, and performance postCP AP therapy, the research does not address the effectiveness of CPAP in relation to
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improving overall objective measures of continuous 24-hour total sleep/wake activity and
energy expenditure. To address this knowledge gap, the present study proposed the use of
actigraphy as a practical, convenient, and cost-effective method to measure
responsiveness to CPAP therapy in terms of sleep/wake activity and energy expenditure.
Furthermore, findings from this study may offer important clinical, social, and economic
implications associated with evaluating CPAP effectiveness, as well as identifying factors
critical to understanding and developing weight loss strategies for the overweight, obese,
and at-risk OSA population.
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CHAPTER III
METHODS
Study Design
This study employed a prospective, observational, longitudinal, and repeated
measures study design, in which data were collected from a single sample of overweight
and obese adults diagnosed with OSA who required CPAP therapy. Primary study
outcomes evaluated changes in 24-hour total sleep activity, wake activity, and energy
expenditure over time as measured via actigraphy. Data were collected at three fixed time
points: prior to CPAP treatment (time point 1 [Tl]), one week post-CPAP treatment
(time point 2 [T2]), and 30 days post-CPAP treatment (time point 3 [T3]). At each time
point, data were collected for 10 consecutive days and included 24-hour sleep activity,
wake activity, and energy expenditure. Ten days was chosen to allow for the inclusion of
both weekday and weekend data, providing a more comprehensive understanding of the
effects of CPAP. Additionally, the pre-CP AP time point selection of a full week was
based on the usual timeframe for clinical scheduling between consultation and diagnostic
PSG. Post-CPAP time points were chosen to evaluate adjacent changes in the outcomes
at the initial one-week pre-CPAP, as well as extended longitudinally to observe distant
changes in the outcomes at the clinical standard of one month post-CPAP. In addition,
prior research concerning compliance data has shown that CPAP use is often
discontinued within the first one to two weeks after beginning treatment (Grunstein,
2005); therefore, the one week post-CPAP was a critical time point for data collection
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and provided the opportunity to collect data from those individuals who did not continue
therapy through the 30-day time point. Furthermore, because CPAP compliance at one
month has shown to be predictive of compliance at 3 months, additional time points were
not included in the current study (Kribbs et aI., 1993; Weaver et aI., 1997).
Sample and Setting
The target population for this study was overweight and obese adults diagnosed
with OSA. Participation was dependent upon a subject's eligibility, willingness to
participate, and signed informed consent. Interested subjects were required to meet the
following inclusion criteria: 1) male or female; 2) adults age 18 to 65; 3) able to speak,
read and write the English language; 4) overweight or obese at baseline (BMI :::25); 5)
initially present with signs and symptoms consistent with OSA and diagnostically
confirmed with an AHI :::5 as determined by PSG; 6) require CPAP therapy (physicianprescribed); and 7) maintain a regular sleep schedule, going to bed routinely between the
hours of 9:00 pm and 1:00 am and allowing 6 to 9 hours of sleep time. Likewise,
potentially eligible subjects were excluded if they met any of the following exclusion
criteria: 1) non-traditional work hours (night shift or swing shift work); 2) any known
acute, unstable, or untreated medical conditions; and 3) pregnant or planning to become
pregnant.
Children and older adults have different sleep architecture and sleep requirements
when compared to adults aged 18 to 65 (Carskadon & Dement, 2005); therefore, it has
been recommended that children and adults older than 65 should be studied
independently, and, as a result, were not recruited for the current study. This research did
not pose a pregnancy risk; however, because both obesity and OSA may be affected
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during pregnancy, pregnant women were excluded from study participation. Night shift
and swing shift workers were not eligible for study participation due to the interrupted
sleep/wake schedules involved in these types of shift work. Those with acute, unstable, or
untreated medical conditions were not included in the study because these conditions
could have affected their ability to undergo sleep study procedures and CPAP treatment.
Minorities were not excluded from study participation.
The sample population obtained for analysis represented a convenience sampling
of patients evaluated at Sleep Medicine Specialists (SMS), a private physician practice in
Louisville, Kentucky. Population demographics were evaluated prior to data collection
and estimated to be 80% adult (ages 18 to 65), 75% male, 85% Caucasian, 75% privately
(non-state funded) health insured, and less than 1% uninsured. Approximately 85% of
SMS patients are either self- or physician-referred for evaluation of OSA. On average,
there are a total of 25 to 30 new sleep patients evaluated each week for OSA; therefore,
subject recruitment and enrollment from this single site seemed feasible to adequately
power this study. SMS is a practice of eight pulmonary physicians, all of whom are
board certified in sleep medicine. In this setting, patients are initially seen for
consultation in an outpatient physician office and subsequently scheduled for overnight
testing in the sleep center. The sleep center is located adjacent to the physician offices.
SMS maintains accreditation by the American Board of Sleep Medicine, and has a total
of 10 diagnostic sleep rooms. The sleep rooms are appointed with standard or queen size
beds, overhead lighting, bedside table, lamp, cable television, sink, and a chair.
Restrooms with showers are located adjacent to sleep rooms.
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Human Subjects Considerations
The protocol and informed consent form (ICF) were approved by the University
of Louisville Human Subjects Protection Program Office (HSPPO). Approval letters can
be found in Appendix A. Subject recruitment material was not needed for subject
enrollment. Eligible men and women, ages 18-65, as well as English-speaking minorities
from the SMS practice, were recruited for this study.
The ICF process was conducted by the investigator in a private exam room, and
included a discussion and explanation of the study purpose and goal, study procedures,
type of data collected, conflicts of interest, study funding or sponsorship, risks and
benefits associated with the study, alternative procedures or treatment of OS A,
compensation, study personnel contact information, and relevant patient confidentiality
and health information protection and privacy issues (Polit & Beck, 2004). It was
expected that study-related procedures would involve minimal risk to subjects. Emphasis
was placed on the voluntary nature of study participation, and that the subject may
withdraw at any time with no fear of their withdrawal from the study affecting their
treatment. The subjects were informed that compensation would not be provided for
study participation. Human subject protection, confidentiality, and health information
privacy was also incorporated into the ICF and reviewed with study participants.
Following a discussion, subjects were allowed adequate time to read the ICF and ask
questions. All questions were answered by the investigator to the subject's satisfaction.
No data collection or other study-related procedures were performed prior to the study
participant signing ICF, and a signed ICF copy was provided to all subjects.

55

There were no conflicts of interest to be disclosed. Specifically, there was no
compensation provided by the investigator to the referring SMS physician, nurse, clinical
staff, or office practice. The investigator was not a clinical practitioner or an employee of
SMS. The physicians, nurses, clinical staff, and investigator followed professional and
ethical conduct and did not use coercive tactics for subject recruitment. Additionally, the
SMS clinical staff and physician practice were not involved in data collection or analysis
of the research.
Measurement
This study focused on changes in wake activity (time in minutes), sleep activity
(time in minutes), and total energy (kilocalorie) expenditure over time, both prior and
subsequent to CPAP therapy. The Actiwatch®-64 and Actical® devices were the
instruments used to obtain these measurements. Philips-Respironics, Inc. provided 10
Actiwatch® and Actical® monitoring devices, the ActiReader hardware, corresponding
software programs, and instruction manuals for each monitoring system. As referenced
in the literature review, most studies have consistently shown actigraphy to be a valid
assessment of sleep patterns with significant correlation to PSG in measuring total sleep
time (Matsumoto et aI., 1998; Hedner et aI.; Vallieres & Morin, 2003). Advantages of
actigraphy include its' cost-effectiveness and ability to non-invasively and objectively
record continuous physical movements during sleep and wake activity in a natural
environment, over extended periods of time (Ancoli-Israel, 2005; Kushida et aI., 2001).
Variables of interest to this study can be referenced in Table 1, with detailed discussion
of each of these variables provided within separate sections labeled as outcome variables,
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Table 1

Variables and Measurement
Variable

Data Collection Instrument

Sleep activity (in minutes)

Actiwatch®

Wake activity (in minutes)

Actiwatch®

Energy expenditure (in kcals)

Actical®

Gender

Clinical Chart - Self-Report Questionnaire

Age

Clinical Chart - Self-Report Questionnaire

Race

Clinical Chart - Self-Report Questionnaire

Education Level

Clinical Chart - Self-Report Questionnaire

Work Status

Clinical Chart - Self-Report Questionnaire

Work Schedule

Clinical Chart - Self-Report Questionnaire

Sleep Schedule

Clinical Chart - Self-Report Questionnaire

Marital Status

Clinical Chart - Self-Report Questionnaire

Height

Clinical Chart

Weight

Clinical Chart

Body Mass Index

Clinical Chart

Child-bearing Potential Status

Clinical ChartlUrine Pregnancy Test

Medical History

Clinical Chart - Self-Report Questionnaire

Apnea-Hypopnea Index

Clinical Chart - Polysomnographic Report

CPAP Pressure

Clinical Chart - CPAP Report

CPAP Compliance

EncorePro® SmartCard®
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demographic variables, OSA and CPAP compliance variables, and height, weight, body
mass index and pregnancy variables.

Outcome variables
Sleep, wake, and energy expenditure (EE) were the outcome variables of interest
in this study and were measured using two wrist-worn actigraphy devices. The Actical®,
as reported in premarket summary, is intended to serve as "a compact, lightweight,
waist,wrist, or ankle worn activity monitor that may be used to assess human gross motor
activity, caloric expenditure and estimates of energy expenditure based on motor activity
in any instance where quantifiable analysis of physical motion is desirable" (Respironics,
Inc®, 2006, pp. 1-5). This device uses an omni-directional piezoelectric accelerometer to
provide measurement of physical motion. The degree of speed and motion produces
voltage reading which is stored as an activity count. Activity counts have cut-point
intensity values and corresponding algorithms for calculating activity energy expenditure
(kcal·kg·min- 1). The Actical® predicts EE and utilizes the Actical®, Version 2.10
software to download data via the ActiReader® device (Respironics, 2007). An example
of Actical® data can be found in Appendix B.
To date, the Actical® has been used in a variety of metabolic, behavioral, activity
and physical exercise research, and has been validated in adult, child, and adolescent
populations (Mini Mitter®, 2003). Heil (2006) developed equations for predicting
activity energy expenditure (AEE) in children and adults using the Actical® device. This
laboratory-based study resulted in regression models with subsequent algorithms for
predicting AEE based on physical activity intensity at three monitoring locations (hip,
ankle and wrist). Heil concluded that these generalized prediction equations and
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corresponding algorithms would provide useful assessment of time-based physical
activity in groups of children and adults, but would likely never "accurately predict AEE
for all activities in all people" (p. 76). Heil suggested monitors that allow for individual
calibration could overcome this limitation; however, such a monitor has yet to be
developed. Heil further reported physical activity and AEE measurement was sensitive to
the body part that is responsible for the motion and that placement of the Actical® limits
the precision of measurement when worn in a single location. In adults, both modeling
algorithms accurately predicted light and moderate activities in all monitor locations but
was most consistent for vigorous activity in the hip location.
Crouter, Churilla & Bassett (2006) conducted a free-living study to examine the
validity of predicted EE regression equations from three accelerometers (including the
Actical®). These researchers compared the three accelerometers to indirect calorimetry
across a range of sedentary to vigorous physical activities. Findings revealed that no
single regression equation offered precise determination of the time spent in a specific
activity intensity or an accurate prediction of corresponding EE.
Rothney, Shaefer, Neumann, Choi and Chen (2008) also conducted a free-living
study to validate EE predications from three different commercially available
accelerometers, including the Actical®. These authors found less than 2% differences in
moderate and vigorous physical activity prediction equations of the accelerometers as
compared to room calorimeter measurements. Sedentary and light intensity activities
tended to either over- or underpredict EE (Rothney et al.). This study offered similar
conclusions as Heil (2006) and Crouter, et al. (2006), indicating the need for developing
new regression equations to establish more accurate predictions of physical activity
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intensity. Lastly, a study conducted by Feeney et al. (2007), addressed the validation of
the Actical® in obese and non-obese middle-aged adults. This study found differences in
currently established AEE and activity count cut-points when comparing the younger
non-obese and middle-aged obese study participants. The results of this study suggested
the need to establish specific age and body composition algorithms for measuring
physical activity and EE with the Actical® accelerometer (Feeney, et al.).
The Actiwatch® includes the Actiware®, Version 5.0 sleep software program to
allow sleep and wake activity data to be downloaded via the ActiReader® and measured
in time (Respironics, 2006). The complex algorithms for scoring and calculating data
have been validated and score sleep and wake based on sampled epochs (15 second, 30
second, 1 minute, or 2 minute) of activity counts. These activity counts are scored as
either sleep or wake depending on whether the number of counts exceeds or falls below
the established intensity thresholds set for sleep and wake. An example of the
Actiwatch® data can be found in Appendix C. Like the Actical®, the Actiwatch® uses
an accelerometer with a sensitivity ofless than .01 g-force to measure physical movement
and produce an electrical current. The intensity of this electrical current is stored as an
activity count and distinguishes wake, sleep, sleep onset, awakenings during sleep, and
total sleep time (Ancoli-Israel, 2005). Kushida et al. (2001) compared actigraphic,
polysomnographic, and subjective assessment of sleep parameters in sleep-disordered
patients. Data for number of awakenings, total sleep time, and sleep efficiency were
compared. Sensitivity, specificity and accuracy were calculated using the low- (highwake-sensitivity), medium- (medium-wake-sensitivity) and high- (low-wake-sensitivity)
threshold algorithms from the Actiware® software program and compared to PSG and
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questionnaire data. Findings from this study were comparable to an earlier study by
Babin, Lee, Halko, Boudreau and George (1997) revealing higher sensitivity (0.98 actigraphic ability to detect sleep) for measuring sleep parameters in sleep disordered
patients with the higher threshold algorithm at the cost oflower accuracy (0.80 actigraphic ability to detect both sleep and wake) and specificity (0.36 - actigraphic
ability to detect wake). Overall, the accuracy of actigraphy in patients with sleep
disorders has been reported to range between 0.78 and 0.85 (Blood, Sack, Percy & Pen,
1997; Oakely, 1997; Sadeh, Hauri, Kripke & Lavie, 1995).
While both the Actical® and Actiwatch have limitations in precision and accuracy
associated with the individual nature of age, body composition, and free-living
differences, each instrument offers validated measurements taken as a group. As such, the
use of these instruments addresses a gap in the literature by combining measures of the
Actiwatch® and Actical® device to measure the influence ofCPAP on sleep/wake
activity and energy expenditure in the overweight and obese OSA study population.

Demographic variables
Demographic variables included gender, age, race, education level, work status
and schedule, sleep schedule, marital status, height, weight, BMI, child-bearing potential
status, and medical history. Medical history data relevant to OSA comorbid conditions
included hypertension, myocardial infarction, heart failure, cerebrovascular accident,
dyslipidemia, diabetes, and depression. A category to capture other medical conditions
was included, as well. Some of these demographic variables were used to ensure
appropriate subject selection based on established eligibility criteria. Otherwise,
demographics were used to describe the sample population. Contact information (name,
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date of birth, home address, and phone numbers) for each subject was collected in the
event the investigator needed to reach the subject. This information (see Appendix D)
was maintained separately from the subject's research data and stored in the coinvestigators secured, limited-access research office.

GSA and CPAP compliance variables
Polysomnography (PSG) was conducted as a routine clinical procedure for the
diagnosis of OSA and CPAP titration. An AHI was obtained from the overnight PSG
report on all subjects to determine if they met eligibility (AHt:5). For those eligible
subjects requiring CPAP, a physician-prescribed CPAP pressure (centimeters of water
pressure) was collected from the CPAP titration PSG study report (filed in the clinical
chart). PSG acquisition, diagnostic scoring, and CPAP titration were conducted following
standard clinical and technical procedures for an accredited sleep center. All clinical PSG
diagnostic and CPAP titration studies were reviewed and interpreted by a SMS board
certified sleep physician. A sample of OSA and CPAP titration in raw data PSG form can
be referenced in Appendices E and F. Additionally, an example of both diagnostic and
CPAP titration PSG reports can be found in Appendices G and H.
CPAP compliance data was obtained from standard CP AP machines equipped
with meters recording CPAP use on a removable card, which was downloaded by the coinvestigator into a computer software program to generate compliance (hours of usage)
reports (see Appendix I). The CPAP machines prescribed from the SMS practice are
manufactured by Philips-Respironics and incorporate the Encore® Pro SmartCard®
technology to monitor and record the date, time and duration of CP AP use over a six
month time period (Respironics, 2009). The Encore® Pro software allows the
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development of a database for management of patient SmartCard® downloads, reports
and compliance tracking. While not collected in the current study, the Encore® Pro
system further records data on pressure trends, tidal volume, respiratory rate, triggered
breathing percentage, minute ventilation, air leaks, and alarms (Respironics, 2009).
Height, weight, body mass index and pregnancy variables
Height and weight, with a calculated BMI were measured by the clinical staff and
obtained from the subject's chart. These variables served as measures for determining
study eligibility based on overweight or obese criteria, as well as for descriptive
purposes. BMI was calculated by the SMS clinical staff, but was confirmed by the
research co-investigator using the standard formula: weight in kilograms divided by
height in meters squared. To meet study eligibility criteria, as required by the local
HSPPO, a urine pregnancy test was conducted on all females of child-bearing potential
(females were considered to be of child-bearing potential unless they reported
spontaneous amenorrhea for at least 12 months or reported having had a hysterectomy
and/or bilateral oophorectomy) to confirm negative urine human chorionic gonadotropin
(HCG).
Data Collection Procedures
Subjects were recruited on a rolling basis from SMS over a 14 month time period,
from November 2009 to January 2011. Clinical patients undergoing initial OSA
evaluation at SMS were informed ofthe opportunity to be involved in a research study.
All sleep nurses and physicians (clinical staft) at SMS were provided information about
the research study and asked to identify potentially eligible subjects. A visit schedule of
procedures can be referenced in Appendix J and data collection forms for all visits can be
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found in Appendix K. All study procedures, with the exception of the urine pregnancy
test and actigraphy (Actiwatch® and Actical®) training/instruction, monitoring,
dispensing/return, and download, were routine standard of care for SMS.
Visit 1.0
Once a subject was deemed eligible and expressed an interest in participating, the
investigator approached the patient to discuss the study purpose and procedures, privacy
and protection of health information, and the risks and benefits of study participation.
Upon the subject's verbal understanding and written signed/dated informed consent, the
investigator proceeded with initial data collection from the subject's clinical chart,
including initials, gender, age, race, education level, work status and schedule, sleep
schedule, marital status, height, weight, BMI, child-bearing potential status, and medical
history (hypertension, myocardial infarction, heart failure, cerebrovascular accident,
dyslipidemia, diabetes, depression, and other). Contact information (home address and
phone numbers) for each subject was also collected and maintained in a separate subject
identification log. This information was used to communicate with the subjects and was
maintained in the investigator's secured, limited-access research office.
To meet the local HSPPO's requirements, a urine pregnancy test was collected on
all females of child-bearing potential to determine pregnancy status during the first visit.
Child-bearing information was obtained from all female subjects by the investigator to
determine the need to collect urine pregnancy test. The subject's clinical chart was
reviewed during Visit 1.0 to determine if the subject met study eligibility. Missing or
unclear demographic information, relevant to the study, was clarified by the investigator
during this visit.
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The subject was then instructed on the use of the Actiwatch® and Actical®
device and asked to wear both wrist devices 24 hours a day (without removing) for 10
days prior to their scheduled diagnostic PSG (one week pre-CPAP data collection). Based
on findings from an earlier unpublished pilot study, a 10 day actigraphy data collection
period was chosen in order to collect a full week (seven days) of continuous 24 hour data
(including five weekdays, Monday through Friday, and two weekend days, Saturday and
Sunday) (McCullough, 2008). This pilot study collected actigraphy data for seven days
but yielded only five days of evaluable data with the starting day (Day 1) and ending day
(Day 7) days having partial data (less than 24 hours).

Visit 2.0 and 2.1
At Visit 2.0, subjects returned for overnight PSG, which was either a diagnostic
PSG with a second CP AP treatment/titration PSG, or a single split diagnostic PSG and
CPAP treatment/titration PSG (split night study). Split night studies are determined by
sleep time and OSA severity per health insurance/medical coverage plans. Whether a
subject underwent a single split diagnostic/treatment night (Visit 2.0) or two nights for
diagnosis and treatment (Visit 2.1) could be considered a potential confounding factor in
the final data analyses. Those study participants who required 2 nights for diagnosis and
treatment experienced a lapse of time between the diagnostic PSG (Visit 2) and the CPAP
treatment/titration PSG (Visit 2.1). This lapse of time was one to two weeks, depending
on the clinical schedule. The AHI (2:5) and prescribed CPAP pressure were collected
from the PSG report filed in the clinical chart. All PSG acquisition and scoring, as well as
CPAP titration, were conducted by a trained SMS PSG technologist and interpreted by a
SMS board certified sleep physician.
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During Visit 2.0, actigraphy data download from both the Actical® and
Actiwatch® was conducted. All eligible subjects were scheduled by the SMS office staff
to return for a routine CPAP set-up office visit. Additional data collected at this visit
included any reported adverse events related to study participation and/or procedures.
Visit 3.0

Subjects returned for a routinely scheduled clinical office visit at SMS for CPAP
set-up. The durable medical equipment company (DME) provided the PhilipsRespironics CPAP equipment, compliance SmartCard®, and necessary training and
instruction on home use of the equipment, as usual and customary. During Visit 3.0, the
investigator saw the subject and provided instruction and training on the use of the
Actical® and Actiwatch® devices. The actigraphy devices were dispensed to the subject
and they were asked to again wear both wrist devices 24 hours a day (without removing)
for approximately forty days starting on the first day of CPAP therapy at home (in order
to obtain both the one week and one month post-CP AP time points for data collection).
Additional data collected at this visit included any reported adverse events related to
study participation and/or procedures.
Phone Contact

Subjects were contacted by the investigator (by phone) approximately 10 to 14
days following the first day of CP AP use at home. This phone contact served to assess
the subject's use of the Actical® and Actiwatch® devices and CPAP therapy. Additional
data collected at this visit also included any reported adverse events related to study
participation and/or procedures.
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Visit 4.0
Subjects returned for a regularly scheduled clinical office visit at SMS after
approximately one month of CPAP treatment home. During Visit 4.0, the investigator
saw the subject and performed a CPAP compliance data download and an actigraphy data
download from both the Actical® and Actiwatch® devices. Additional data collected at
this visit included any reported adverse events related to study participation and/or
procedures. This visit concluded study participation for the subject.
With the exception of PSG acquisition and scoring and CPAP titration, all data
collection and procedures involving the Actiwatch® and Actical® devices and related
subject visits were conducted by the co-investigator. Total subject duration in the study
was dependent on clinical diagnostic and treatment scheduling with an expected duration
of about two months.
The initial office visit, PSG, CPAP titration, CPAP machine/supplies/compliance
card, and any associated education or instruction is considered standard care for OSA
patients and was subject to usual healthcare billing procedures by SMS and the DME
company. The training and use of the Actiwatch® and Actical® device did not fall under
usual care and was considered a study-related procedure. Subjects were not compensated
for any standard of care procedures or study-related procedures.
Data Management Procedures
Unique identifiers were assigned to each subject to maintain anonymity (except to
those directly involved in the research). Each subject had a 3 digit number consecutively
assigned beginning with 001. All study participant information was stored in the
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investigator's secured, limited-access research office. Furthermore, all research data were
collected, maintained, and entered for statistical analysis by the investigator.
Statistical Analysis
Descriptive analysis
Data analyses were performed using SPSS version 17.0 (SPSS, 2008). Study
demographics were obtained for the entire sample, and descriptive statistics were
calculated. Differences in demographic variables between those subjects who completed
all study time points and those who did not complete all study time points were tested
using t-test for continuous variables and Chi-square tests for categorical variables. The
analytic sample was then dichotomized into CPAP compliant (~ 4 hours/night on 70% of
the observed nights) and CPAP noncompliant « 4 hours/night on 70% of the observed
nights) to test for differences between these two groups. These differences were tested
using Chi-square techniques for all categorical data and t-tests for all continuous
variables, utilizing an alpha of 0.05.
Inferential analysis
Three separate two-factor repeated measures analysis of variance (ANOVA)
models were developed to detect overall group differences between pre-CPAP (T 1), 1
week post-CPAP (T2), and 30 days post-CPAP (T3) on 24-hour sleep, wake, and energy
expenditure. Repeated measures ANOVA allowed for group comparisons of the three
study variables at different points over time (Munro, 2005), specifically testing for main
effects for group (CP AP compliant versus CP AP non-compliant) and time. Utilizing
repeated measures offered the ability to decrease the error term, while requiring fewer
subjects to increase the power of the analysis (Munro). Although this study did not
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involve a random sample, the research met other ANOVA assumptions, which included
continuous dependent variable observed across mutually exclusive groups (the dependent
variable observations are independent) and equal variances (homogeneity) across the
groups on the dependent variable (observations on the dependent variable follow a
normal distribution in each group) (Stevens, 2002).
While repeated measures ANOV A is an omnibus test, post-hoc comparisons are
needed if an effect is seen for variables with more than two levels (e.g., three time
points). As such, paired (-tests techniques were performed to test the sub-hypotheses for
differences between two time points. The analyses conducted allowed for exploration of
the following hypothesized outcomes (hypothesis I [HI], hypothesis 2 [H2], hypothesis 3
[H3]):

HI) Subjects will have a significant decrease in total 24-hour sleep activity over time
as a result of using CPAP (measured by the Actiwatch®)
Hla. compared to pre-CPAP, there will be a significant decrease in 24-hour
total sleep activity (time in minutes) 7 days post-CPAP
Hib. compared to pre-CPAP, there will be a significant decrease in 24-hour
total sleep activity (time in minutes) 30 days post-CPAP
H2) Subjects will have a significant increase in total 24-hour wake activity over time
as a result of using CPAP (measured by the Actiwatch®)
H2a. compared to pre-CP AP, there will be a significant increase in 24-hour
total wake activity (time in minutes) 7 days post-CPAP
H2b. compared to pre-CPAP, there will be a significant increase in 24-hour
total wake activity (time in minutes) 30 days post-CPAP
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H3) Subjects will have a significant increase in energy expenditure over time as a
result of using CPAP therapy (measured by the Actical®)
H3a. compared to pre-CP AP, there will be a significant increase in 24-hour
total energy (kilocalorie) expenditure 7 days post-CPAP
H3b. compared to pre-CPAP, there will be a significant increase in 24-hour
total energy (kilocalorie) expenditure 30 days post-CPAP
The first hypothesis 1 (H 1) examined the effect CPAP had on sleep activity; H2
examined the effect CPAP had on wake activity; and H3 explored the effect CPAP had
on energy expenditure. For each outcome, separate repeated measures ANOVA models
were developed.

Sample size calculation
An a priori statistical power analysis was conducted using the G*power 3.0

program to determine the number of subjects required to adequately power the repeated
measures ANOVA analysis and study design (Faul, Erdfelder, Lang, & Buchner, 2007).
The program's field options were populated to include a single group, within factor
ANOVA with 3 time points. Because the magnitude of the relationship (treatment effect)
of CPAP treatment on sleep/wake activity and energy expenditure has not been well
established in prior research, the estimated effect size used for the sample size calculation
was set at a 0.25, defined as a moderate effect size using Cohen's d (Cohen, 1988). The
effect size chosen is also consistent with effect sizes routinely reported in the social
sciences and nursing research (Polit & Beck, 2008; Cohen). Additionally, correlation
occurs when repeated measures are obtained from the same individual over time, with
adjacent time points being more correlated than distant time points. Therefore, the
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correlation values were set at 0.5 for adjacent time points (Tl, T2 and T2, T3) and 0.25
for the distant time points (Tl, T3). The desired power was set at 0.80 with a 0.05 test
significance level. Using these parameters, a sample size of 34 was needed to achieve an
actual power of 0.81. That is, to adequately power the current study, 34 subjects were
needed to complete all three data collection time points.
In order to obtain a final sample size of 34, an attrition rate had to be anticipated.
It has been reported that 58% to 80% of patients either initially refuse or do not continue

CPAP treatment following a trial (Basner, 2007; Grunstein, 2005); however, objective
monitoring of CP AP compliance has more accurately revealed about 46% of OSA
patients used CPAP 4 hours or more on at least 70% of the observed nights, with
compliance at one month predictive of compliance at 3 months (Kribbs et aI., 1993;
Weaver et aI., 1997). Using a 54% attrition rate to conservatively estimate total sample
size, it was projected that 74 subjects needed to be recruited and enrolled in order to
obtain n=34 at T3. The observed attrition rate was slightly less than 54%, requiring only
69 enrolled subjects (51 % attrition). Study recruitment ceased once 34 individuals
completed all three data collection time points. All remaining enrolled subjects were
allowed to continue through all study protocol procedures, with a total of 35 subjects
completing all three time points. The enrollment period for this study was slightly over
14 months. The first subject was consented November 17,2009, and the final subject
completed study participation on January 27, 2011.
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CHAPTER IV
RESULTS
A total of 69 subjects were initially consented and enrolled into the current study.
Of the 69 consented, six did not complete a diagnostic sleep study (PSG) and six did not
demonstrate an AHI 2: 5. The remaining 57 subjects qualified for CPAP treatment;
however, seven did not elect this form of therapy, leaving 50 eligible study participants
completing pre-CPAP time point 1 (n=50). Twelve (24%) of these 50 subjects did not
complete the one week post-CPAP time point (n=38) and 3 did not complete the one
month post-CPAP time point (n=35). Figure 2 (Study Flow Diagram) illustrates the
study enrollment and participation process.
Descriptive Statistics
Eligible sample

Demographic variables for the eligible subjects (n=50) were obtained and can be
referenced in Tables 2 and 3. The mean age for the eligible sample was 49.3 years and
52% were male. The mean body mass index (BMI) was 37.5, the average apneahypopnea index was 26.9, and the mean CPAP pressure was 9.96 cm H 2 0. The sample
was 82% Caucasian, with African-American comprising the remaining 18%. More than
one-third (38%) ofthe sample reported a high school education level, with 28.0%
reporting a college graduate level (16 years of education). Only 2% had less than 12

72

Figure 2. Study Flow Diagram.
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]

~
Consented (n=69)

~
Excluded (n= 19)
o Not meeting inclusion criteria (n= 12)
• 6 did not complete diagnostic PSG
• 6 had an AHI <5
o Declined CPAP treatment (n=7)

~

I

Eligible Participants (n=50)

~

I

l Data Collection Time Points/Analvses
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Time Point 1 (TI) - Pre-CPAP (n=50)

~
Time Point 2 (TI) - 7days Post-CPAP (n=38)
• Did not wear Actiwatch®IActical® (n=7)

•

Discontinued CPAP (n=5)

~
Time Point 3 (T3) - 30 days Post-CPAP (n=35)
• Incomplete CP API Actiwatch®1Actical® data (n=3)
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Table 2

Descriptive Data o/Eligible Subjects - Continuous Variables
Minimum

Maximum

Mean (SD)

Age

28

65

49.3 (10.47)

BMI

27.3

60.9

37.5 (7.41)

Am

5.3

135.3

26.9 (24.49)

CPAP Pressure

6.0

16.0

9.9 (2.91)

Variable
Eligible Subjects (n=50)

74

Table 3

Descriptive Data of Eligible Subjects - Categorical Variables
Variable

Eligible Subjects
n=50 (%)

Gender
Male
Female

26 (52.0%)
24 (48.0%)

Ethnicity
Caucasian
African American

41 (82.0%)
9 (18.0%)

Education
<12 years
High School
TechNocational
College Grad (14yrs)
College Grad (16yrs)
College Grad (lSyrs)

1 (2.0%)
19 (38.0%)
5 (10.0%)
14 (28.0%)
7 (14.0%)
4 (8.0%)

Marital Status
Single
Married
Divorced
Widowed
Separated

11 (22.0%)
31 (62.0%)
5 (10.0%)
1 (2.0%)
2 (4.0%)

Work Status
Unemployed
Part-time
Full-time
Disabled
Retired

6 (12.0%)
7 (14.0%)
29 (58.0%)
5 (10.0%)
3 (6.0%)
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years of education and 8% reported post-graduate education. The majority were married
(62%), with 22% single, 10% divorced, 2% widowed, and 4% separated. Work status
revealed 58% full-time workers, 14% part-time workers, 12% unemployed, 10%
disabled, and 6% retired. Hypertension was the most frequently reported medical
condition by 21 subjects, followed by 11 reporting dyslipidemia. A list of additional
medical conditions reported by the sample of eligible subjects has been summarized in
Table 4. There were seven subjects who had reported no medical history.
Completed and early-term sample comparisons

The sample (n=50) was stratified into completed subjects (n=35) and early-term
subjects (n=15). Completed subjects (n=35) were those participants who completed all
three time points (Tl, T2, and T3) for the study. Early-term subjects (n=15) were those
who completed only the first two time points (Tl and T2). To determine if demographic
differences existed between these groups, t-tests were performed on all continuous
variables and Chi-square techniques on all categorical data, with the significance test
level at 0.05 (see Table 5).
Of the eligible study participants (n=50), the completed subjects were
significantly older (p=.026) than the early-term subjects (51.4 versus 44.3 years). BMI
was also statistically different (p=.013), with those completing the study having a lower
mean BMI (35.8 versus 41.3). The completed subjects group included more males
(57.1 %) than the early term subjects (40%), but was not found to be significantly
different. Both groups were predominately Caucasian. The average AHI (22.9) and
CPAP pressure (9.7) was lower for those who completed compared to those who did not
(36.1 and 10.4, respectively), but was not significantly different. The majority of each of
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Table 4

Medical Conditions Reported by Eligible Subjects
Eligible Subjects

Medical History

n=50(%)
Hypertension

21 (42%)

Dyslipidemia

11 (22%)

Diabetes

9 (18%)

Depression

9 (18%)

Chronic Pain

9 (18%)

Gastric Reflux

6 (12%)

Arthritis

6 (12%)

AsthmalAllergies

3 (6%)

Polycystic Ovaries

2 (4%)

Seizure Disorder

2 (4%)

Heart Attack

1 (2%)

Heart Failure

1 (2%)

Stroke

1(2%)

Migraines

1 (2%)

Celiac Disease

1 (2%)

7 (14%)

None
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Table 5

Demographic Data Comparison o/Completed and Early-Term Subjects
Variable

Completed Subjects
n=35 (%)

Early-Term Subjects
n=15 (%)

p-value

Age

51.4 (10.62)

44.3 (8.45)

.026*

Gender
Male

20 (57.1%)

6 (40.0%)

.266

Ethnicity
Caucasian

31 (88.6%)

10 (66.7%)

.065

Education
<12 years
High School
TechIVocational
College Grad (14yrs)
College Grad (16yrs)
College Grad (18yrs)

1 (2.9%)
15 (42.9%)
1 (2.9%)
9 (25.7%)
7 (20.0%)
2 (5.6%)

0(0.0%)
4 (26.7%)
4 (26.7%)
5 (33.3%)
0(0.0%)
2 (13.3%)

.508
.279
.010*
.582
.062
.363

Marital Status
Single
Married
Divorced
Widowed
Separated

7 (20.0%)
22 (62.9%)
3 (8.6%)
1 (2.9%)
2 (5.7%)

4 (26.7%)
9 (60.0%)
2 (13.3%)
0(0.0%)
0(0.0%)

.602
.849
.607
.508
.345

4 (11.4%)
5 (14.3%)
21 (60.0%)
2 (5.7%)
3 (8.6%)

2 (13.3%)
2 (13.3%)
8 (53.3%)
3 (20.0%)
0(0.0%)

.849
.929
.662
.123
.242

BMI

35.8 (7.27)

41.3 (6.38)

.013 *

Am

22.9 (18.99)

36.1 (33.05)

.080

9.7 (2.75)

10.4 (3.31)

.489

Work Status
Unemployed
Part-time
Full-time
Disabled
Retired

CPAP Pressure

*Indicates statistical significance at the .05 level.
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the samples was married, having at least a high school education, and working full-time.
While overall education status was similar for both groups, there was a statistically
significant difference detected in TechnicalNocational education level (p=.010), with
those not completing the study having a higher percentage of technical/vocational
education (26.7%) as compared to those completing the study (2.9%).
Compliant and noncompliant sample comparisons

The sample of completed subjects (n=35) was stratified into CPAP compliant (~ 4
hours/night on 70% of the observed nights) and CPAP noncompliant « 4 hours/night on
70% of the observed nights) groups for analysis. Table 6 outlines CPAP compliance for
the completed study participants. CPAP compliance for those completing the study
(n=35) was, on average, 313.6 minutes (5.2 hours) per night. The compliant group
(n=21) at T2 (7 days post-CPAP) had a minimum, maximum, and mean use of219.7
minutes (3.7 hours), 594.9 minutes (9.9 hours), and 396.3 minutes (6.6 hours) per night,
respectively. Minimum CPAP use per night at T2 for the noncompliant group (n=14)
was 38.0 minutes, with a maximum usage of 521.0 minutes (8. 7 hours), and an average
use of273.6 minutes (4.6 hours). Compliance dropped for the noncompliant group at T3,
with the minimum number of minutes used per night 0.0, a maximum use of267.6 (4.5
hours), and average use of 180.6 (3.0 hours). Compliance improved for the compliant
group at T3, with minimum, maximum, and mean minutes of271.0 (4.5 hours), 638.9
(10.6 hours), and 402.3 (6.7 hours). As noted in Table 7, when compliant subjects (n=21)
were compared to the noncompliant (n=14) completed subjects, there were no significant
differences found on any of the demographic variables tested.
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Table 6
CPAP Compliance for Completed Subjects
CPAP Compliance

Minimum
MinuteslNight

Maximum
MinuteslNight

Average
MinuteslNight

Total Group (n=35)

0.00

638.90

313.59(138.69)

Time Point 2
Compliant (n=21)

219.70

594.90

396.27(92.89)

NonCompliant (n=14)

38.00

521.00

273.56(140.76)

Time Point 3
Compliant (n=21)
NonCompliant (n=14)

271.00

638.90

402.26(90.03)

0.00

267.60

180.59(78.02)
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Table 7
Demographic Data Comparison ojCPAP Compliant and Noncompliant Subjects
CPAP Compliant
Subjects (n=21)
48.8(11.59)

CPAP Noncompliant
Subjects (n=14)
55.4(7.74)

p-value

Gender
Male

12 (57.1 %)

8 (57.1%)

1.000

Ethnicity
Caucasian

19 (90.5%)

12 (85.7%)

.664

Education
<12 years
High School
TechIVocational
College Grad (14yrs)
College Grad (16yrs)
College Grad (l8yrs)

0(0.0%)
9 (42.9%)
0(0.0%)
5 (23.8%)
5 (23.8%)
2 (9.5%)

1 (7.1 %)
6 (42.9%)
1 (7.1%)
4 (28.6%)
2 (14.3%)
0(0.0%)

.214
1.000
.214
.752
.490
.234

Marital Status
Single
Married
Divorced
Widowed
Separated

4 (19.0%)
12 (57.1 %)
3 (14.3%)
1 (4.8%)
1 (4.8%)

3 (21.4%)
10 (71.4%)
0(0.0%)
0(0.0%)
1 (7.2%)

.863
.392
.139
.407
.766

1 (4.8%)
3 (14.3%)
15 (71.4%)
0(0.0%)
2 (9.5%)

3 (21.4%)
2 (14.3%)
6 (42.9%)
2 (14.3%)
1 (7.1 %)

.129
1.000
.091
.075
.805

BMI

34.9(5.99)

37.0(8.95)

.415

Am

22.2(19.49)

24.0(18.87)

.782

10.1(2.79)

9.2(2.67)

.334

Variable
Age

.071

Work Status
Unemployed
Part-time
Full-time
Disabled
Retired

CPAP Pressure

*Indicates statistical significance at the .05 level.
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Repeated Measures Analysis of Variance
Three separate repeated measures ANOVA tests (Table 8) were performed for
each of the outcome variables. Measures of sleep activity, wake activity, and energy
expenditure were entered into the ANOVA models to test for group effects (mean
differences in each outcome variable between CPAP compliant and noncompliant
groups), a time effect (mean differences in each outcome variable between time points)
at baseline [TI], 7 days post-CPAP [T2], and 30 days post-CPAP [T3]), and a group x
time interaction effect (mean differences among the compliant or noncompliant groups at
any ofthe time points). As shown in Table 8, all three models demonstrated a significant
group effect with all p-values <0.001. Both sleep (p=.OI4) and wake (p=.024)
demonstrated significant time effects; however, neither outcome had significant
interaction effects (p=.838 and p=.997, respectively). Energy expenditure was not found
to have a significant time effect (p=.260) or interaction effect (p=.878).
Figures 3, 4, and 5 graphically depict sleep activity (minutes), wake activity
(minutes), and energy expenditure (kilocalories) over time, stratified by compliance,
respectively. In Figure 3, sleep shows an increased sleep activity time in both compliant
and noncompliant groups from TI-T2, and a continued increase from TI to T3. Both
groups had decreased wake activity time from TI-T2 with a continued decline from TIT3. While not statistically significant, Figure 5 shows a decrease in energy expenditure
for both groups from TI-T2, with both the compliant and noncompliant groups showing a
continued decrease from TI-T3. Although this research was interested in only measuring
pre-CPAP (TI) to one week post-CPAP (T2) and one month post-CPAP (T3), the results
for EE from repeated measures ANOVA (see Figure 5) showed an increase in EE from
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Table 8
Repeated Measures ANOVA ofSleep Activity, Wake Activity, and Energy Expenditure
Over Time Stratified by Group

Outcome

Predictors

F

p-value

Sleep Activity

Compliance

501.6

<.001 ***

Time

6.801

.014 ***

Compliance*Time

0.42

.838

Compliance

1214.5

Time

5.620

.024 ***

Compliance*Time

0.000

.997

Compliance

647.3

Time

1.312

.260

Compliance*Time

0.024

.878

Wake Activity

Energy Expenditure

***Indicates statistical significance at the .05 level.
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<.001 ***

<.001 ***

Figure 3. Sleep Activity Over Time Stratified by Compliance
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Figure 4. Wake Activity Over Time Stratified by Compliance
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Figure 5. Energy Expenditure Over Time Stratified by Compliance
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T2 to T3 in the CP AP noncompliant group.
Paired t-tests
Paired t-tests (Tables 9 and 10) were performed to provide more detailed
information and allowed examination of mean differences in each variable from Tl to T2
(n=38) and Tl to T3 (n=35) for the entire group, and both compliant and noncompliant
groups. Sleep time increased from pre-CPAP (baseline) to 7 days post-CPAP (one week)
and 30 days post-CPAP (one month) regardless of compliance status. Statistically
significant differences in sleep were demonstrated in the total group (p=.004) and
compliant group (p=.012) from TI-T2, and the total group (p=.010) and noncompliant
group (p=.007) from TI-T3. Wake time showed a decrease across the same time points
for all groups, with significant decreases for the total group (p=.009) and compliant group
(p=.031) from TI-T2, and the total group (p=.019) and noncompliant group (p=.008)
from T 1-T3. Energy expenditure revealed decreases in all groups, across both time
points, although not significant. While an increase in energy expenditure from T2 to T3
can be seen in Figure 5 for the noncompliant group, additional analyses (Table 11) found
this change was not statistically significant (p=.315).
Consistent with repeated measures ANOVA testing, there were total group
differences noted for sleep activity and wake activity from TI-T2 and TI-T3~ however,
energy expenditure did not reveal any significant differences for the total group between
any time points. Interestingly, mean differences in sleep and wake were significant in the
compliant group from TI-T2, but were not from TI-T3. Conversely, significant
differences in sleep and wake were observed in the noncompliant group from TI-T3, but
not from Tl-T2. Likewise, repeated measures ANOV A demonstrated significant group
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Table 9

Paired t-tests: Sleep Activity, Wake Activity, and Energy Expenditure Stratified by Group
at Adjacent Time Points 1 to 2
Outcome Variable

Baseline

One Week

Mean

p-

Pre-CPAP

Post-CPAP

Difference

value

Tl

T2

TI-T2

Minutes(SD)

Sleep Activity
Total group (n=38)

526.4(115.8)

585.4(27.5)

59.0(116.9)

.004*

Compliant (n=27)

532.2(116.3)

596.8(169.7)

64.6(124.9)

.012*

Noncompliant (n=l1)

512.l(118.8)

557.4(173.4)

45.2(98.7)

.l59

Minutes(SD)

Wake Activity
Total group (n=38)

908.9(117.0)

854.2(169.7)

-54.7(123.2)

.009*

Compliant (n=27)

901.1(117.6)

842.6( 170.1)

-58.6(133.4)

.031*

Noncompliant (n=l1)

927.8(118.8)

882.6(173.4)

-45.2(98.8)

.160

Energy Expenditure

Kllocalories(SD)

Total group (n=38)

4285.8(908.3)

4183.6(982.3)

-102.3(527.0)

.239

Compliant (n=27)

4265.0(856.7)

4132.9(985.6)

-132.l(554.6)

.227

Noncompliant (n=l1)

4336.8(1067.7)

4307.7(1010.4)

-29.l(468.6)

.841

*Indicates statistical significance at the .05 level.
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Table 10

Paired t-tests: Sleep Activity, Wake Activity, and Energy Expenditure Stratified by Group
at Distant Time Points 1 to 3
Outcome Variable

Baseline

One Month Post

Mean

p-

Pre-CPAP

CPAP

Difference

value

Tl

T3

TI-T3

Minutes(SD)

Sleep Activity
Total group (n=35)

516.4(112.9)

594.6(201.5)

78.1(168.5)

.010*

Compliant (n=21)

501.8(96.7)

584.8(230.7)

82.9(209.0)

.084

Noncompliant (n=14)

53 8.4( 134.5)

609.2(154.7)

70.9(83.6)

.007*

Wake Activity

Minutes(SD)

Total group (n=35)

918.4(114.7)

848.0(199.9)

-70.4(169.6)

.019*

Compliant (n=21)

929.6(101.4)

859.4(227.9)

-70.3(210.6)

.142

Noncompliant (n=14)

901.5(134.5)

831.0(154.9)

-70.5(83.8)

.008*

Energy Expenditure

Kllocalories(SD)

Total group (n=35)

4315.5(937.3)

4189.6(1042.0)

-125.9(611.3)

.231

Compliant (n=21)

4354.1(794.6)

4214.9(1014.3)

-139.2(704.2)

.376

Noncompliant (n=14)

4257.6(1149.0)

4151.6(1119.9)

-105.9(462.4)

.407

*Indicates statistical significance at the .05 level.
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Table 11

Paired t-tests: Sleep Activity, Wake Activity, and Energy Expenditure Stratified by Group
at Time Points 2 to 3
Outcome Variable

One Month

One Month Post

Mean

p-

Post-CPAP

CPAP

Difference

value

T2

T3

T2-T3

Minutes(SD)

Sleep Activity
Total group (n=35)

572.8(161.1)

594.6(201.5)

21.8(84.2)

.135

Compliant (n=21)

558.8(170.9)

584.8(230.7)

26.0(94.3)

.220

Noncompliant (n=14)

593.8(148.8)

609.2(154.7)

15.5(69.2)

.418

Minutes(SD)

Wake Activity
Total group (n=35)

866.7(161.5)

848.0(199.9)

-18.7(80.8)

.180

Compliant (n=21)

881.1(171.1)

859.4(227.9)

-21.8(89.5)

.279

Noncompliant (n=14)

845.2(149.6)

831.0( 154.9)

-14.2( 68.8)

.454

Energy Expenditure

Kilocalories(SD)

Total group (n=35)

4234.8(1007.7)

4189.6(1042.0)

-45.2(335.2)

.430

Compliant (n=21)

44303.5(1000.7)

4214.9(1014.3)

-88.6(394.3)

.315

Noncompliant (n=14)

4131.7(1046.9)

4151.6(1119.9)

-19.9(216.8)

.737

*Indicates statistical significance at the .05 level.
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effect in energy expenditure, but paired t-tests failed to reveal statistically significant
mean differences for the total group, compliant group, or noncompliant group. While
these findings seem counterintuitive, they are consistent with Simpson's Paradox, in
which a correlation or trend is observed when groups are stratified to test for marginal
effects, but becomes non-significant when groups are combined (Cohen, 1988). This is
often a result of confounding factors and caution should be exercised in making causal
inferences about the data (Cohen), specifically the effect of CPAP on sleep activity, wake
activity, and energy expenditure.
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CHAPTER V
DISCUSSION
Introduction
The purpose of this research was to examine the influence of CPAP on sleep
activity, wake activity, and energy expenditure. Overweight (BMI::: 25) and obese (BMI

> 30) adult patients with OSA (AHI::: 5) were the targeted population for this study, as
their risk of comorbidities are greater than those non-overweight/obese OSA patients.
Sleep activity, wake activity and energy expenditure were measured prior and subsequent
to initiating CPAP therapy, testing for differences that exist before and after therapy over
time. A conceptual model (Figure 1, p. 5) was developed to provide the framework for
assessing overweight/obesity (BMI), OSA (polysomnography-AHI), sleep activity
(actigraphy), wake activity (actigraphy), energy expenditure (actigraphy) and CPAP
compliance (internal compliance meter). The propositions linking these variables
included the relationships between overweight/obesity and OSA, how sleep
fragmentation/disruption and daytime fatigue/sleepiness are associated with OSA, and
how these concepts link OSA to increased sleep activity and decreased wake activity,
with a decrease in 24-hour total energy expenditure. The model further included CP AP
treatment affecting sleep consolidation (less sleep fragmentation/disruption), improving
wakefulness (less daytime fatigue/sleepiness), and how (respectively) these concepts
negatively correlate CPAP treatment (and level of compliance) with sleep activity, and
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positively correlate CPAP therapy with wake activity and 24-hour total energy
expenditure.
Findings
As stated in the hypotheses, and following the conceptual framework, the net loss
of total 24-hour sleep activity and gain in total 24-hour wake activity was expected to
result in an overall increase in total 24-hour energy expenditure following CPAP
treatment; however, the statistical analyses demonstrated the following findings relative
to the 3 hypothesized study outcomes.

Hypothesis I
The first study hypothesis stated that subjects would have a decrease in sleep
activity as a result of using CP AP, with decreases in 24-hour total sleep activity, both 7
days and 30 days post CPAP, as compared to pre-CPAP. The results actually showed the
following:

HI) Subjects had a statistically significant increase in sleep activity as a result of
using CPAP (measured by the Actiwatch®)
Hla. compared to pre-CPAP, there was a statistically significant increase in
24-hour total sleep activity (time in minutes) 7 days post-CPAP
HIb. compared to pre-CPAP, there was a statistically significant increase in
24-hour total sleep activity (time in minutes) 30 days post-CPAP
The results demonstrated statistically significant increases in total 24-hour sleep
activity, in minutes, from the pre-CPAP time point (baseline) to both the one week and
30 day post-CPAP time points. Contrary to what was hypothesized, the subjects in this
study showed a statistically significant increase in their 24-hour sleep activity, with
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statistically significant differences between the CPAP compliant and noncompliant
groups. When paired t-tests were performed from Tl to T2, the total group (n=38) and
the CP AP compliant group (n=27) had statistically significant mean differences in sleep
activity. While from TI-T3, it was the total group (n=35) and noncompliant group (n=14)
who had statistically significant differences in mean sleep activity.
At baseline, all subjects were exceeding 8 hours (>480 minutes) of sleep activity
time over 24 hours (see Tables 9 and 10), with a minimum mean sleep time of 501.8
minutes. They continued to exceed 8 hours and extend their 24 hour total sleep activity
time following CP AP treatment at the seven day and 30 day time points. A graph (Figure
3, p. 84) generated from repeated measures ANOVA further illustrates this point and
shows group differences, with noncompliant subjects having more sleep activity time at
each of the three time points as compared to the compliant subjects. There are no
empirical studies to either support or negate these findings, only anecdotal references and
clinical observations to offer mixed thoughts about the effect of using CPAP on sleep
time. Clinically, patients report sleeping fewer hours and feeling more refreshed, so it is
difficult to determine ifthese study subjects were sleeping longer as a consolidated sleep
period at night or had more total sleep activity time because they were more sedentary or
napping during the day, at any of the measured time points. This is a limitation of using
actigraphy alone to measure ambulatory sleep activity for this study; however, this device
has demonstrated reliability in distinguishing sleep and wake when compared to
electroencepaholgraphic measures with polysomonography, and the results can be
interpreted with a fairly high degree of confidence (Ancoli-Israel, 2005; Kushida et aI.,
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2001; Babin, Lee, Halko, Boudreau & George, 1997; Blood, Sack, Percy & Pen, 1997;
Oakely, 1997; Sadeh, Hauri, Kripke & Lavie, 1995).
Hypothesis 2
The second study hypothesis stated that subjects would have an increase in wake
activity as a result of using CPAP, with increases in 24-hour total wake activity, both 7
days and 30 days post CPAP, as compared to pre-CPAP. The results actually showed the
following:
H2) Subjects had a statistically significant decrease in wake activity as a result of
using CPAP (measured by the Actiwatch®)
H2a. compared to pre-CPAP, there was a statistically significant decrease in
24-hour total wake activity (time in minutes) 7 days post-CPAP
H2b. compared to pre-CPAP, there was a statistically significant decrease in
24-hour total wake activity (time in minutes) 30 days post-CPAP
Again, contrary to what was hypothesized, the subjects in this study showed a
statistically significant decrease in their 24 hour wake activity. Results of repeated
measures ANOV A detected statistically significant group (compliant and noncompliant)
and time differences in total 24 hour wake activity (in minutes) from the pre-CPAP time
point (baseline) to both the one week and 30 day post-CPAP time points without
significant interaction between groups or time points. Because there were only two
groups, post-hoc testing was not conducted. Likewise, because there was no evidence of
statistically significant interaction between groups and time, further data analyses was not
performed. Interestingly, paired t-tests revealed the total group (n=38) from T1 to T2 and
compliant group (n=27) to have statistically different mean wake activity times, but from
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Tl to T3 the total group (n=35) and noncompliant group (n=14) showed statistically
different wake activity time means. From baseline through T2, the compliant subjects had
more mean wake activity time (and less mean sleep activity time) than the noncompliant
subjects, which was just the opposite from baseline to T3. This finding is not fully
understood and cannot be explained by differences in the demographic data collected, as
there were no statistically significant differences between groups. Further exploration of
this should be considered in future studies.
Hypothesis 3
The third study hypothesis stated that subjects would have an increase in energy
expenditure as a result of using CPAP, with increases in 24-hour total energy
expenditure, both 7 days and 30 days post CPAP, as compared to pre-CPAP. The results
actually showed the following:
H3) Subjects had a decrease (not statistically significant) in energy expenditure
subsequent to initiating CPAP therapy (measured by the Actical®)
H3a. compared to pre-CPAP, there was a decrease (not statistically
significant) in 24-hour total energy (kilocalorie) expenditure 7 days postCPAP
H3b. compared to pre-CPAP, there was a decrease (not statistically
significant) in 24-hour total energy (kilocalorie) expenditure 30 days postCPAP
Energy expenditure was not found to have a statistically significant time effect;
therefore the study hypothesis for this outcome was not supported; however, repeated
measures ANOV A detected statistically significant group differences among the CPAP
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compliant and noncompliant (see Table 8). Paired t-tests were performed (Tables 9 and
10), but were unable to confirm any statistically significant differences in EE in the total,
compliant, and noncompliant groups, across any time point. Number of calories burned

decreased, rather than increased, for both the CP AP compliant and noncompliant groups
from T1 to T2 and T1 to T3, with the compliant group expending more energy than the
noncompliant group at all time points.
Conclusions
These study findings were the opposite of what was hypothesized, with increased
total 24-hour sleep activity time, decreased total 24-hour wake activity time, and
decreased total 24-hour energy expenditure, regardless of CPAP treatment or level of
compliance. The groups had statistically significant mean differences in sleep activity and
wake activity from pre-CPAP to post-CPAP at one week and one month; however the
direction of change was consistent for both groups, with sleep activity increasing and
wake activity decreasing. At baseline, and continuing through T2 and T3, the CPAP
compliant group showed less sleep activity, more wake activity, and more calories burned
than the noncompliant group. When assessing demographics of the compliant versus
noncompliant groups, there were no significant differences in any of the variables tested
to account for this finding.
CPAP compliance was an important variable in this study and has a wide degree
of variance in the literature, with ranges from 46 to 80% (Basner, 2007; Grunstein, 2005;
Kribbs et aI., 1993; Weaver et aI., 1997). In this study, approximately 71 % were
compliant after the first week of home use, and approximately 60% were compliant after
one month of home use. While not expected, subjects in this study had greater sleep
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activity, less wake activity, and expended less energy after using CPAP, whether they
were compliant or not. Empiric evidence has shown CPAP to decrease the number of
arousals and awakenings during sleep due to apneic events; however, this did not
translate to more consolidated/less total 24 hour sleep or greater 24 hour wake time/more
physical activity for this group of study participants. Furthermore, these findings showed
fewer calories burned post-CPAP, but differences in energy expenditure were not
statistically significant.
Unfortunately there is no direct link to or succinct explanation for this study's
findings; however, two relatively recent publications by West, Kohler, Nicoll, &
Stradling (2009) and Otake et al. (2010) studied the effect of CPAP on sleep/wake
activity using actigraphy. West et al. studied 36 men with OSA and found there were no
significant differences in activity levels one week before the initiation of CPAP as
compared to one week after CPAP therapy. Otake et al. confirmed agreement between
PSG and actigraphy data and determined subjects treated after one month of CPAP had
significantly less activity levels/movement than prior to CPAP. Both the effects of OSA
and CPAP therapy on sleep/wake activity and energy expenditure remain unclear and
lack sufficient empirical evidence to support the current study results.
This study has shown that OSA subjects using CPAP have more sleep activity
than prior to treatment, subsequently reducing 24-hour total wake activity time. Less
wake time, combined with fewer arousals and awakenings due to apnea, could feasibly
reduce total caloric expenditure. Although there was not a statistically significant
decrease in daily energy expenditure following CPAP use, the decline in calories burned
following CP AP treatment may be a longer term factor in weight gain for OSA patients.
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Implications
This research was adequately powered to demonstrate that CPAP use is a
statistically significant factor affecting sleep activity time, wake activity time, and energy
expenditure. Regardless ofCPAP compliance (nightly hours) and length of use (one
week or one month), the entire post-CPAP group demonstrated more sleep activity, had
less wake activity, and burned fewer calories. This would potentially translate to an
increase in weight over time. From a clinical perspective, the results of this study do not
support the use of CPAP as a potential weight loss measure in overweight and obese
OSA patients, and emphasize the need for the inclusion of behavioral weight
management and weight loss strategies in an at-risk population for comorbid illnesses.
The extended use of actigraphy in both the research and practice setting would be a
beneficial adjunct to monitoring sleep/wake activity and energy expenditure and set
behavioral goals and outcomes. Studies have shown that those who self-report sleeping
fewer hours (.:::..6 hours/day) tend to gain weight (Hayes, Xu, Babineau, & Patel, 2011; )
and have higher incidences of circulating leptin (adipose-derived hormone) and
adipokines (immunomodulating cytokines secreted by adipose tissue) levels (Hayes, et
al.). These high levels have been linked to greater risk of increased inflammatory markers
contributing to cardiovascular and cerebrovascular disease, insulin resistance, and
diabetes (Leinum, Dopp, & Morgan, 2009; Vgontzas, Zoumakis, & Bixler, 2004); Patel,
Zhu, & Storfer-Isser, 2009).
The current study showed those who completed the study (n=35) were older and
had a lower BMI than those who did not complete the study (n=15). These were the only
statistically significant differences among demographics. The outcomes of this study

99

may have been quite different had the 30% early-term subjects completed the study. This
is also an important consideration for recruitment and retention for future research. Of
the entire completed sample (n=35), there were no statistically significant differences in
demographic findings between those who were compliant with CPAP and those who
were not. Interestingly, those who completed all 3 time points averaged more than 8
hours of sleep both before and after CP AP treatment. This could be a result of actigraphy
recording sleep during waking sedentary activity. Possibly, previous research utilizing
subjective sleep report may underestimate true sleep time. Again, this may support the
use of actigraphy in combination with subject sleep/wake diaries in both research and
practice.
Limitations
While those patients who are unable to speak, read, write and understand the
English language were excluded from study participation, this did not pose a significant
restriction to recruitment, as the practice setting this sample was drawn from does not
typically have a high percentage of non-English speaking patients. However, external
validity and generalizability was limited for several reasons. Choosing only one practice
setting had the disadvantage of not having a more heterogeneous group, and including
only one group did not allow for a control group or group comparisons, other than
compliance. For this study, the inclusion of several sites and patient groups was cost
prohibitive and not feasible without additional research staff. Conversely, an advantage
to a single site and group was efficiency, consistency and better control of patient care
and follow-up, diagnostic testing, scoring of data, and titration of CPAP.
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To reduce threats to internal validity, acknowledgement and control of as many
identified confounding variables as possible was exercised; however, the apparent
Simpson's Paradox observed during data analyses revealed the likely influence of such
variables. Some of these variables were anticipated and accounted for in the
inclusion/exclusion criteria and CPAP compliance data. The use of subjective sleep
diaries, and activity and food diaries (during the days of Actiwatch® and Actical® use)
would have offered further support and/or explanation of data and should be considered
in future studies. Additionally, ANOVA assumes subjects will be randomly assigned to
either a control or treatment group, so that two groups do not have any systematic
difference except for the treatment applied. This study design involved non-random
assignment; however, in the case of self-selection, the repeated measures treatment effect
model was expected to produce reliable estimates of the mean differences.
The study was further limited by the possibility that pre- and post-CPAP
differences in sleep/wake activity and energy expenditure may be detected as a result of
subject response to study participation and knowledge of what is being measured rather
than real change (Munro, 2005). A repeated measures study design was expected to
provide some control against such contrived patient activity, or even variation in activity
levels related to individual and situational factors at the time of measurement. An
extension of this longitudinal study may have offered more robust findings.
Recommendations
Research in the area of sleep/wake and energy expenditure in overweight and
obese OSA patients has become increasingly important and clinically relevant in a
population where the incidence of OSA, weight gain, and resulting comorbid illness
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continues to rise (Leinum, Dopp, & Morgan, 2009). There is an abundance of evidence
linking OSA, obesity, cardiovascular disease, metabolic risk, and the benefit of CPAP
therapy; however, there is limited data regarding the effect CPAP treatment has on sleep,
wake, and energy expenditure in an ambulatory and long-term setting. Although the
results of this study failed to support the conceptual framework developed to guide the
study hypotheses, this study offers a substantial review of past and currently available
literature and provides a foundation for future clinical investigation. The current
conceptual framework and hypotheses were developed from the existing body of
knowledge in this field which was heavily weighted on anecdotal studies and clinical
observation, further highlighting the need for greater empirical testing. Additional
research in overweight and obese patients with OSA is needed, and should be pursued
with model revision of sleep/wake and energy expenditure concepts that link OSA with
obesity, cardiovascular disease and metabolic dysfunction as a framework for larger
prospective studies.
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Board Designee: Martinez, Serge
Letter Sent By: Block, Sherry, 4/19/2011 11 :03 AM
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Continue following the regulations below:
1.
Unanticipated problems or serious adverse events encountered in this research
study must be reported to the IRS within five (5) working days.
2.
Any modifications to the study protocol or informed consent form must be
reviewed and approved by the IRS prior to implementation.
3.
You may not use a modified informed consent form until it has been approved
and validated by the IRS.

filII Accreditation since JUlie 1005 by IIII! Association/or tire Accreditation of
Humoll Research ProJection Programs, JIlC.
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Appendix C
Actiwatch® Report

Actiware Print Report
Analysis Name: New Analysis
Subject 10:
K-S 002

Date of Birth:

Gender:

Data Collection Start:

Data Collection End: 7/8/2008, 1:16:30 PM

Actiwatch SN:

7/1/2008, 2:53:00 PM

I

8:00 PM

12:00 PM

V963450

I

6:00 AM

12:00 PM

6:00 AM

12:00 PM

,
12:00 PM

Printed: 7/812008, 1:21 :29 PM

6:00 PM

12:00 AM
Mini Mitt., Company, Inc.
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Page 2

Actiware Print Report
Analysis Name: New Analysis
K-S 002
Subject 10:
Data Collection Start:

71112008, 2:53:00 PM

Date of Birth:

Gender:

Data Collection End: 7/8/2008,1:16:30 PM

AcUwatch SN:

V963450

Dail],! Interval Statistics
Q2l1!

Start Date

StartTlme

End Date

EndTlme

1
2
3
4

7/1/2008

2:53:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM

71212008
71312008

12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
12:00:00 PM
1:16:30 PM

5
6
7
8
n
Averageln)
Std DevIn-I)

Q2l1!
1
2
3
4

5
6
7
8
n
Averageln)
Std Dev(n-l)

7/212008
71312008

7/4/2008
7/5/2008
7/6/2008
7rr12008
7/8/2008

.

%lnvalldAC
(%)
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
8
0.00
0.00

Printed: 7/812008, 1:21:29 PM

"&!Invalid llW
(%)
0.16
0.00
0.00
0.00
0.00
0.00
0.00
2.61
8
0.35
0.92

71412008
71512008
71612008

m12008
71812008
71812008

.

.

15.00
B
807.00
335.14

%Wake
(%)
58.02
64.85
74.10
68.09
60.42
6B.44
60.42
20.13
8
59.31
16.69

Mini Mltter Company, Inc.
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TotalAC
(eounts)
264330
297981
406074
378322
328551
424050
299030
5572
8
300488,76
131775.19

SleepTlme
(minutes)
531.00

~
(counts/mlnute)
208.63
206.93
282.00
282.72
228.16
294.48
207.66
72.84

MaxAC
(counts)
1448
1858
3054
1746
2870
1640
1858
723

8

8

22D.43
69.07

1899.62
751.86

%Sleap
(%)
41.98
35:14
25.90
31.91
39.58
31.56
39.58
79.87
8
40.69
15.59

Page 4

Appendix D
Subject Information Log
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Appendix G
Obstructive Sleep Apnea Polysomnography Report

Sleep Medicine SI1ecia1ists
1169 Eastern Parkway, Suite #3357
Louisville, Kentucky 40217
Phone 502..454.Q755
Fax 502..454.3497

Polysomnogram (PSG)
Patient name:

Date of bIrth:
Physidan:
Axis A/ICSD:

Test date:
Test type:
1 Study

1 Patient ID #:

#: I 9080

Dear.'••

Dr. David Winslow
780.53-0
1120922

We appreciate your referral of this patient to our services for Polysomnography. The 15 channel overnight study
consists of a combination of EEG, Chin EMG, EOG, leg EMG, thoradc and abdomInal wall movements, nasal/oral
airflow, ECG, Sa02, body position, and tracheal sound. The results are as follows:
I Weight:

I Age: 1 44

I Height: I Sft:.l0in.

1 2061bs.

Medications: Reglan,Protonlx,Lexapro
Sleep Staging

I Ughts Out: 11:04:47 PM

Sleep stage

Stage N1
Stage N2
StaQe N3 (delta)
Stage R (REM)
Stage W (wake)

1 Lights On: 1:16:47 AM

Sleep duration

% of time in bed

2.5 min.
99.0 min.
11.5 min.
0.0 mIn.
19.0 min.

1.9
75.0
8.7
0.0
14.4

Normal values

(5%)
(50%)
(15%1
(20%)
(10%)

%
%
%
%
%

Respiratory

I 41 of events
I Mean duration
I Max. duration

Central
0
0.0
0.0

Aoneas
Obstructive
42
18.9
24.5

Total Index
82.3

Mixed
0
0.0
0.0

REM Index

HypClJ:!neas
113
21.3
41.5

Total
155

Non·REM Index
82.3

Page 1
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Body Position
Duration (min.)

0/0 asleep

AHI

80.3

97.8

89.4

36.2

95.3

66.1

Uo
Supine
Left Side
Suoine Left
Prone Rlqht
Prone
Supine Rleht
Rieht Side

~==~~~~7::":----+--=~-+~ Minimum 02 Value

Heart Rate
Mean Heart Rate (BPM)
Lowest Heart Rate (BPM)
Hlehest Heart Rate BPM

Total number of WK or MVf episodes
Arousal index
'Yo of pages with arousal during sleep

REM

Wake
74.6
55
137

Non-REM
67.0
46
113

6
B7.6/hr (sleep)
71.2

Page 2
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Sleep Medicine Specialists
1169 Eastern Parkway, Suite #3357
Louisville, Kentucky 40217
Phone 502.454.0755
Fax 502.454.3497

Polysomnogram (PSG)

The patient tolerated NPSG well with loud snoring and OSA observed. There were a total of 155
respiratory abnormalities with an apnea/hypopnea index (AHI) of 82.3 (average number of apneas/
hypopneas per hour of sleep-a value greater than 5.0 is considered abnormal). Oxygen saturation
dropped to 77% during the recording. ECG recording revealed no ECG abnormalities. The patient will
follow up with Dr. David Winslow for sleep study results.

Physician's Impression:

Physidan's Signature:

Very Severe Obstructive Sleep Apnea Syndrome

_-1>[£<-1-,'\....d<....;;;--'~c;,..;.;.
__________
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Appendix H
CPAP Titration Polysomnography Report

Sleep Medicine Specialists
1169 Eastern Parkway, Suite #3357
Louisville, Kentucky 40217
Phone 502.454.0755
Fax 502.454.3497

CPAP Titration

Referring Physlcian:_

I Age: 44 years

I Height: Sft.101n.

I Welght:206Ibs.

Medications: Reglan,Protonlx,Lexapro
SleeP Staging

I Ughts Out: 1:18:47 AM

Sleep stage

I Ughts On: 6:01:47 AM

'Yo of time in bed

Sleep duration

StageNl
Stage N2
StaQe N3 (delta)
Stage R (REM)
Stage W (wake)

9.5
146.0
50.0
55.0
22.5

min.
min.
min.
min.
min.

3.4
51.6
17.7
19.4
8.0

'Yo
%
%
'Yo
%

Normal values
(5%)
(50%)
(15%)
(20%)
(10%)

Minimum 02 value:

Unit Requested:
Mask Type:
Mask Size:

Ramp TIme:
Oxygen Therapy:
Oxygen Flow:
Chin5trap:

CPAP M-Series{Heated Humidification
Comfort Select
Small
20 Minutes
Not Required
Not Required
Yes

Lowest Pressure Tried:

5

em H20

Highest Pressure Tried:

12

em H20

Final Optimal Pressure:

9

cmH20

136

Sleep Medicine SpedaI1sts
1169 Eastern Parkway, Suite #3357
Louisville, Kentucky 40217
Phone 502.454.0755
Fax 502.454.3497

CPAP Titration

~:d_
CPAP was titrated to a pressure of 9 em/H20 with no significant GSA obsesved, and the patient tolerated CPAP
well. It is recommended that the patient follow up with Dr. David Winslow within one month for CPAP
compliance therapy.

dvJ{Vv'-~~

Physician Slgnature _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
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Appendix I
CP AP Compliance Report

Sleep Medidne Specialists
1169 Eastern Parkway
Suite 3310
Louisville, Ky 40217 United States

Device: REMstar Auto M Series with A-Flex ( SlOM )

Compliance Details - Full Report

,tient:

Interaction Date: 7/8/200812:~8 PM

.u1nilSlsIl1ltes.···

Patient ID

1398

Home Phone
Age

Referring Physician:
Group/Prnctice
Phone
Fax
E-Mail Address

PCP:
Phone

Clinician:

Compliance Information 7/1/2008 - 7/7/2008
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Appendix K
Data Collection Forms

Visit 1.0 (Initial Sleep Evaluation, Pre-CPAP)
Date of Visit: _ _ _ _ _ _ _ _ _ _ _ _ _ __
Informed Consent Process:
Date ofInformed Consent: ---------------------- Version: ---------------Study procedures, risks, benefits, and other relevant study information were explained to the
subject. Subject was allowed to ask questions and all questions were answered completely by
assigned study staff. Subject was given a copy of the signed ICF. The subject signed the ICF
prior to the performance of any study-related procedures.

y N Checklist:
Subject is able to read, write, and comprehend the English language?
Subject read and verbalized understanding of the informed consent?
Adequate time was allowed?
All questions were answered to the subject's satisfaction?
Subject signed and dated the informed consent?
A copy was provided to subject for his/her records?

Individual conducting consent process: _____________________________D.ate: _______

Date of Birth: ____________ Age: _ _ _ (18-65)
Gender: Male / Female
Race:
Caucasian descent
Asian descent
African descent
American Indian or Alaskan Native
Native Hawaiian or Other Pacific Islander
Other (specify): ______________________________________
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Marital Status:
Single
Married
Divorced
Widowed
Other:
Education level: (highest level obtained)
<12 years
High School Diploma (12 years)
TechnicalNocational School
CollegelUniversity Undergraduate (14 years)
CollegelUniversity Undergraduate (16 years)
CollegelUniversity Graduate (18 years)
CollegelUniversity Post-Graduate (18+ years)
Work Status:
Unemployed
Part-time
Full-time
Disabled
Work Schedule:
Day shift
Evening shift
Night shift
Swing shift
Sleep Schedule:
Usual bedtime: _ _ _ _ _ _ _ Usual time of awakening: _ _ _ __
Medical History:
Hypertension
Myocardial infarction
Heart failure
Cerebrovascular accident
Dyslipidemia
Diabetes
Depression
Other (specify): _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Any acute, unstable, or untreated medical conditions?
Yes:- - - - - - - - - - - - - - - - - - - - - - - - - - No

Height: __"_in ___ " cm

Weight: _ __

lbs

BM!:
kg.;-~m)2= _ __
(weight kg) .;- [height (m)]2
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Child-bearing Potential: Female of childbearing potential?
Yes/No: ------------------ N/A: _ _ _ _ _ _ _ __
Urine Pregnancy Test Results: Positive/Negative

N/A

Expiration/Lot #: __________________
Eligibility Review: (all must be marked yes, "Y", for study inclusion)
1) male or female;
2) adults age 18 to 65;
3) able to speak, read and write the English language;
4) overweight or obese (BMI ~25);
5) initially present with signs and symptoms consistent with OSA, which is newly and
diagnostically confirmed with an AHI ~5 as determined by PSG;
6) require CP AP therapy (physician-prescribed);
7) maintain traditional work hours (no night shift work);
8) go to bed between 9:00 pm and 1:00 am, allowing 6 to 9 hours of sleep time;
9) no known acute, unstable, or untreated medical conditions; and
10) not pregnant or planning to become pregnant.
Actigraphy:
Subject instructed on the use of the Actiwatch® and Actical® devices:
Yes/No----------------Actiwatch® dispensed: _______________
Actical® dispensed: _________________
Subject asked to wear both wrist devices 24 hours a day (without removing) for ten days prior to
their scheduled diagnostic PSG: Yes/No

--------------

Diagnostic PSG scheduled per SMS clinical staff:
Yes: Date of PSG:- - - - - - - - - - - - No: Explain: _ _ _ _ _ _ _ _ _ _ _ _ _ ___

Signature of individual completing source documents
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Date

Visit 2.0/2.1 (Diagnostic PSG/CP AP Titration)
Date of Visit: _ _ _ _ _ _ _ _ _ _ _ _ _ __
PSG:
Split diagnostic/CPAP titration
Diagnostic only
ApneaIHypopnea Index: _ _ __
CPAP Titration PSG scheduled per SMS clinical staff:
Yes: Date ofCPAP Titration PSG: _ _ _ _ _ _ _ _ _ _ __
No: Explain: _ _ _ _ _ _ _ _ _ _ _ _ __
N/A
CPAP Pressure: _ _ _ _ _cm H2O
Eligibility Review: (must be marked yes, "Y", for study inclusion)
•
•

OSA diagnostically confirmed with an AHI ~5 as determined by PSG;
require CP AP therapy (physician-prescribed);

Actigraphy:
Subject returned Actiwatch® and Actical® devices:

YeslNo

----------

Actiwatch® data downloaded: start date._ _ _ _ _ _ _.....;/end date_ _ _ _ _ _ __
Day 1: Total sleep minutes: _ _ _ _ _ Total wake minutes:. _ _ _ _ __
Day 2: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 3: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 4: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 5: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 6: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 7: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 8: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 9: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 10: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
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Actical® data downloaded: start date._ _ _ _ _ _ _--'/end date,_ _ _ _ _ _ _ __
Day 1: Total EE:, _ _ _ _ __
Day 2: Total EE:, _ _ _ _ __
Day 3: Total EE:, _ _ _ _ __
Day 4: Total EE:, _ _ _ _ __
Day 5: Total EE:, _ _ _ _ __
Day 6: Total EE: _ _ _ _ __
Day 7: Total EE: _ _ _ _ __
Day 8: Total EE: _ _ _ _ __
Day 9: Total EE: _ _ _ _ __
Day 10: Total EE:, _ _ _ _ __

Adverse Events: (related to study participation and/or procedures)
yes: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
No

CPAP set-up scheduled per SMS clinical statT: _ _ _ _ _ _ __
Comments:

Signature of individual completing source documents
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Date

Visit 3.0 (CPAP Set-Up, Post-CPAP)
Date of Visit: _ _ _ _ _ _ _ _ _ _ _ _ _ __

Actigraphy:
Subject instructed on the use of the Actiwatch® and Actical® devices:
Yes/No-----------------

Actiwatch® dispensed: _____________
Actical® dispensed: _______________
Subject asked to wear both wrist devices 24 hours a day (without removing) for approximately 40
days starting with the first day of CPAP use at home:
Yes/No_________________
CPAP:
CPAP compliance card included with CPAP equipment: Yes/No_________________
Adverse Events: (related to study participation and/or procedures)
Yes: ________________________________________________________________
No
One Month Follow-Up visit scheduled per SMS clinical statT: _ _ _ _ _ _ __
Comments:

Signature of individual completing source documents

146

Date

Phone Contact (Post-CPAP, At Home)
Date of Phone Contact: _ _ _ _ _ _ _ __
Actigraphy:
Assess use of Actiwatch® and Actical® devices at home: YeslNo

----------------

Comments:- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

CPAP:
Assess use ofCPAP at home: YeslNo
---------Comments: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ___

Adverse Events: (related to study participation and/or procedures)
Yes: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ____
No

Confirm One Month Follow-Up visit scheduled per SMS clinical staff: _ _ _ _ _ _ __

Comments:

Signature of individual completing source documents
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Date

Visit 4.0 (One month Post-CPAP)
Date of Visit: _ _ _ _ _ _ _ _ _ _ _ _ _ __

Actigrapby:
Subject returned Actiwatch® and Actical® devices:

Yes~o

________________

Actiwatcb® data downloaded: start date,_ _ _ _ _ _ _~/end date,_ _ _ _ _ _ __
Day 1: Total sleep minutes: ______ Total wake minutes: ___________
Day 2: Total sleep minutes: ______ Total wake minutes: _________
Day 3: Total sleep minutes: _______ Total wake minutes: ___________
Day 4: Total sleep minutes: ______ Total wake minutes:, ___________
Day 5: Total sleep minutes: _______ Total wake minutes: ________
Day 6: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 7: Total sleep minutes: ______ Total wake minutes: _ _ _ _ __
Day 8: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ ___
Day 9: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ ___
Day 10: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 11: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ ___
Day 12: Total sleep minutes: ______ Total wake minutes: _______
Day 13: Total sleep minutes: _ _ _ _ _ Total wake minutes: _______
Day 14: Total sleep minutes: ______ Total wake minutes:, _______
Day 15: Total sleep minutes: ______ Total wake minutes:, _______
Day 16: Total sleep minutes:, ______ Total wake minutes:, _______
Day 17: Total sleep minutes:, _______ Total wake minutes: _ _ _ _ __
Day 18: Total sleep minutes:, _______ Total wake minutes: _ _ _ _ __
Day 19: Total sleep minutes: _ _ _ _ _ Total wake minutes: _______
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Actiwatch® data downloaded (continued): start date_ _ _ _....:/end date_ _ _ _ __

Day 20: Total sleep minutes: _ _ _ _ _ Total wake minutes: _ _ _ _ __
Day 21: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 22: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 23: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 24: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 25: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 26: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 27: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 28: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 29: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 30: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 31: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 32: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 33: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 34: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 35: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 36: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 37: Total sleep minutes:

Total wake minutes:- - - - - -

Day 38: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 39: Total sleep minutes:

Total wake minutes: _ _ _ _ __

Day 40: Total sleep minutes:

Total wake minutes: _ _ _ _ __
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Actical@datadownloaded:start date,_ _ _ _ _ _ _/end date,_ _ _ _ _ _ _ __
Day 1: Total EE:

Day 21: Total EE:, _ _ _ _ __

Day 2: Total EE:

Day 22: Total EE:, _ _ _ _ __

Day 3: Total EE:

Day 23: Total EE:, _ _ _ _ __

Day 4: Total EE:

Day 24: Total EE:, _ _ _ _ __

Day 5: Total EE:

Day 25: Total EE:, _ _ _ _ __

Day 6: Total EE:

Day 26: Total EE:, _ _ _ _ __

Day 7: Total EE:

Day 27: Total EE: _ _ _ _ __

Day 8: Total EE:

Day 28: Total EE: _ _ _ _ __

Day 9: Total EE:

Day 29: Total EE: _ _ _ _ __

Day 10: Total EE:

Day 30: Total EE: _ _ _ _ __

Day 11: Total EE:

Day 31: Total EE: _ _ _ _ __

Day 12: Total EE:

Day 32: Total EE: _ _ _ _ __

Day 13: Total EE:

Day 33: Total EE: _ _ _ _ __

Day 14: Total EE:

Day 34: Total EE: _ _ _ _ __

Day 15: Total EE:

Day 35: Total EE: _ _ _ _ __

Day 16: Total EE:

Day 36: Total EE: _ _ _ _ __

Day 17: Total EE:

Day 37: Total EE:. _ _ _ _ __

Day 18: Total EE:

Day 38: Total EE:. _ _ _ _ __

Day 19: Total EE:

Day 39: Total EE: _ _ _ _ __

Day 20: Total EE:

Day 40: Total EE:, _ _ _ _ __
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CPAP:

Subject provided CPAP compliance card: yes/No_ _ _ _ _ _ _ __
CPAP compliance data downloaded: start date_ _ _ _ _ _....;'end date_ _ _ _ _ __

Day 1: Hours of use: _ _ _ _ _ __

Day 21: Hours ofuse: _ _ _ _ _ __

Day 2: Hours ofuse: _ _ _ _ _ __

Day 22: Hours ofuse: _ _ _ _ _ __

Day 3: Hours of use: _ _ _ _ _ __

Day 23: Hours of use: _ _ _ _ _ __

Day 4: Hours ofuse: _ _ _ _ _ __

Day 24: Hours ofuse: _ _ _ _ _ __

Day 5: Hours of use: _ _ _ _ _ __

Day 25: Hours ofuse: _ _ _ _ _ __

Day 6: Hours ofuse: _ _ _ _ _ __

Day 26: Hours of use: _ _ _ _ _ __

Day 7: Hours ofuse: _ _ _ _ _ __

Day 27: Hours ofuse: _ _ _ _ _ __

Day 8: Hours ofuse: _ _ _ _ _ __

Day 28: Hours ofuse: _ _ _ _ _ __

Day 9: Hours of use: _ _ _ _ _ __

Day 29: Hours ofuse: _ _ _ _ _ __

Day 10: Hours of use: _ _ _ _ _ __

Day 30: Hours ofuse: _ _ _ _ _ __

Day 11: Hours of use: _ _ _ _ _ __

Day 31: Hours of use: _ _ _ _ _ __

Day 12: Hours ofuse: _ _ _ _ _ __

Day 32: Hours ofuse: _ _ _ _ _ __

Day l3: Hours ofuse: _ _ _ _ _ __

Day 33: Hours ofuse: _ _ _ _ _ __

Day 14: Hours ofuse: _ _ _ _ _ __

Day 34: Hours ofuse: _ _ _ _ _ __

Day 15: Hours ofuse: _ _ _ _ _ __

Day 35: Hours ofuse: _ _ _ _ _ __

Day 16: Hours ofuse: _ _ _ _ _ __

Day 36: Hours ofuse: _ _ _ _ _ __

Day 17: Hours ofuse: _ _ _ _ _ __

Day 37: Hours ofuse: _ _ _ _ _ __

Dayl8: Hours ofuse: _ _ _ _ _ __

Day 38: Hours ofuse: _ _ _ _ _ __

Day 19: Hours ofuse: _ _ _ _ _ __

Day 39: Hours ofuse: _ _ _ _ _ __

Day 20: Hours ofuse: _ _ _ _ _ __

Day 40: Hours ofuse: _ _ _ _ _ __

Adverse Events: (related to study participation and/or procedures)

yes: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
No
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End of Study
Comments:

Signature of individual completing source documents
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2006-2007

SanofI-Aventis EFC6220: Efficacy and Safety of Eplivanserin 5mg/day
on Sleep Maintenance Insomnia: a 6-Week, Multicenter, Randomized,
Double-Blind, Placebo-Controlled Study.
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Merck 022-01: A Multicenter, Randomized, Double-Blind, "Factorial"
Design Study to Evaluate the Lipid-Altering Efficacy and Safety ofMK0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) in
Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia.
Novartis CVEA489A2302: An 8-Week, Multicenter, Randomized,
Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of
the Combination ofValsartanlHCTZ/Amlodipine Compared to
ValsartanlHCTZ, ValsartaniAmlodipine, and HCTZ/Amlodipine in
Patients With Moderate to Severe Hypertension.
Merck 315: A Double-Blind, Randomized, Parallel, Efficacy Study
Evaluating Losartan Potassium Alone or in Combination with
Hydrochlorothiazide versus Placebo in Obese Patients with Elevated
Systolic and Diastolic Blood Pressure.
XenoPort, Inc. XP055: An Open-Label, 52-Week Extension Study
Assessing XP 13 512 Safety and Efficacy in Patients with Restless Legs
Syndrome.
Takeda 01-05-TL-375-067: A Phase2, Double-Blind, Randomized,
Placebo-Controlled, Parallel-Group, Multi-Center Proof-of-Concept Study
to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination
with Doxepin for the Treatment of Subjects with Chronic Insomnia.
GlaxoSmithKline 103660: A 12-Week, Multi-Center, Double-Blind,
Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography
Study of Ropinirole Controlled Release for Restless Legs Syndrome
(RLS) in RLS Patients with Sleep Disturbance and Periodic Limb
Movements (PLM) During Sleep.
Merck 023: a Worldwide, Multicenter, Double-Blind, Randomized,
Parallel Study to Evaluate the Efficacy ofMK-0524 to Improve
Tolerability of Extended Release Niacin.
XenoPort, Inc. XP052: A Randomized, Double-Blind, PlaceboControlled Study to Assess the Efficacy and Safety ofXP13512 in
Patients with Restless Legs Syndrome.
Schwarz SP793: An Open-Label Extension Trial to Investigate the Safety
and Tolerability of Long-Term Treatment with Transdermal Rotigotine
in Subjects with Idiopathic Restless Legs Syndrome.
2006

Sanofi-Aventis LTE6262: Efficacy and Safety of Eplivanserin 5mg/day
on Sleep Maintenance Insomnia: a 12-Week Multicenter, Randomized,
Double-Blind, Placebo-Controlled Study Followed by an Open Treatment
Phase Extension with Eplivanserin for a 40 Week Period.
Merck 022: A Multicenter, Randomized, Double-Blind, "Factorial"
Design Study to Evaluate the Lipid-Altering Efficacy and Safety of
MK-0524B Combination Tablet in Patients With Primary
Hypercholesterolemia or Mixed Hyperlipidemia.
Merck 024: A Multicenter, Randomized, Double-Blind, Parallel Group,
12 Week Study to Evaluate the Efficacy and Safety ofMK-0524B Versus
Atorvastatin in Patients with Mixed Hyperlipidemia.
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Takeda 01-0S-TL-37S-068: A Study of the Safety of Ramelteon with
Moderate to Severe Chronic Obstructive Pulmonary Disease.
200S-2006

Schwan SP792: A Multi-Center, Randomized, Double-Blind, PlaceboControlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and
Safety of Four Different Transdermal Doses of Rotigotine in Subjects
with Idiopathic Restless Legs Syndrome.
Kyowa 6002-US-201: A Phase 2, Double-Blind, Placebo Controlled,
Randomized Parallel-Group, Multicenter Study to Evaluates the Efficacy
and Safety of 40mg/day KW-6002 (Istradefylline) in Subjects with
Restless Legs Syndrome.
Somaxon SP-OS03: A Phase III, Randomized, Double-Blind, Placebo
Controlled, Parallel-Group, Multicenter Study to Assess the Long Term
Efficacy and Safety of Doxepin HCI in Primary Elderly Insomnia Patients
with Sleep Maintenance Difficulties.
Takeda EC302: A Randomized, Double-Blind, Placebo-Controlled Study
to Determine the Long-Term Efficacy and Safety of Ramelteon in Adults
with Chronic Insomnia.
Cephalon CI09S3/3046IES/uS: A Short-Term (8-Week) Open-Label
Study, Followed by a Long-Term Evaluation, to Assess Patient Reported
Outcomes with Armodafinil Treatment (ISO to 2S0 mg/day) for
Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep
Apnea/Hypopnea Syndrome (OSAHS).

200S

GlaxoSmithKline 1001468/20S: A 12 Week, Double-Blind, PlaceboControlled, Parallel-Group Study to Assess the Efficacy and Safety of
Ropinirole XR (Extended Release) in Patients with Restless Legs
Syndrome.
Takeda 01-04-TL-37 S-041: A Randomized, Double-Blind, Placebo
Controlled Study to Assess the Subjective Response to Treatment with
Ramelteon (TAK-37S) in Adult Subjects With Chronic Insomnia by
Utilizing an Interactive Voice Response System (IVRS) for Collecting
Diary Data.
Neurocrine NBI-34060-MR-OS01: A Phase III, Randomized, DoubleBlind, Placebo Controlled, Polysomnographic Study to Assess the
Efficacy and Safety of a Modified Release Formulation ofNBI-34060 in
Primary Insomnia Patients with Sleep Maintenance Difficulties.
Somaxon SP-OSOl: A Phase III, Randomized, Double-Blind, Placebo
Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and
Safety of Doxepin HCL in Primary Insomnia Patients with Sleep
Maintenance Difficulties.

2004-2007

Merck 002-00: A Double-Blind, Randomized, Placebo-Controlled,
Multicenter, 30-Night Polysomnographic Study ofMK-0928 in Elderly
Patients with Primary Insomnia
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Oscient OS-OOl/FORCE: A Phase IV, Stratified, Randomized,
Prospective, Unblinded, Active-Control Trial of Factive Versus Biaxin
XL for the Treatment of Community-acquired Pneumonia and Versus
Amoxicillinlclavulante for the Treatment of Acute Bacterial
Exacerbation of Chronic Bronchitis.
2004-2006

Merck 004-00: A Double-Blind, Randomized, Placebo-Controlled,
Multicenter, 30-night Polysomnographic Study ofMK-0928 in Adult
Patients with Primary Insomnia. 2004-2006.
Cephalon, Inc. Cl0953/3024/ESIMN:A l2-Month, Open-Label,
Flexible-Dosage (100 to 250 mg/day) Extension Study of the Safety and
Efficacy of CEP-l0953 in the Treatment of Patients With Excessive
Sleepiness Associated With Narcolepsy, Obstructive Sleep
ApnealHypopnea Syndrome, or Chronic Shift Work Sleep Disorder.

2004-2005

Altana Pharma BY2l7/M2-023: A Randomized, Controlled Study of
Roflumilast (250 mcg and 500 mcg) Versus Placebo in Patients with
Asthma. A 24-Week, Multicenter, Multinational, Double-Blind, Parallel
Group Clinical Study.
Cephalon Inc, CEP-10953 Cl0953/30211APIMN: A l2-Week,
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to
Evaluate the Efficacy and Safety ofCEP-l0953 (150 and 250 mg/day) as
Treatment for Adults With Residual Excessive Sleepiness Associated
with Obstructive Sleep ApnealHypopnea Syndrome.

2004

Aventis MlO0907C/2004: A North American, 4-Week, Multicenter, Phase
IIB Double-Blind, Placebo-Controlled, Randomized, Multiple Dose,
Parallel-Group Study of the Efficacy and Safety of 0.5 mg, 1.0 mg, and
2.0 mg M1 00907 Tablets in the treatment of Sleep Maintenance Insomnia.
Sanofi-Synthelabo LTE5407: Evaluation ofthe Long-Term Efficacy and
Safety of Zolpidem-MR 12.5mg Compared to Placebo, when Both are
Administered Over a Long-Term Period "As Needed", in Patients with
Chronic Primary Insomnia. (A Randomized, Double Blind, PlaceboControlled, Parallel Group, Multicenter, Phase IIIb Clinical Study).
Pfizer A9001243: A Study To Define The Non-Restorative Sleep
Population.
GlaxoSmithKline 100013: A 12 Week, Double-Blind, Placebo
Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety
of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)
Requiring Extended Treatment Coverage.

2003-2004

Orphan Medical, Inc. OMC-SXB-22: A Randomized, Double-Blind,
Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial
Comparing the Effects of Orally Administered Xyrem (sodium oxybate)
and Modafinil with Placebo in the Treatment of Daytime Sleepiness in
Narcolepsy.
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GlaxoSmithKline 101468/249: A 12 Week, Double-Blind, Placebo
Controlled, Parallel Group Study to Assess the Efficacy and Safety of
Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).
2003

Orphan Medical, Inc. OMC-SXB-15: A Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the
Effects of Orally Administered Xyrem (Sodium Oxybate) with Placebo
for the Treatment of Narcolepsy.
Orphan Medical, Inc. OMC-SXB-19: An Open Label, Multi-Center
Safety Trial studying the Effects of Orally Administered Xyrem (Sodium
Oxybate).
Takeda 01-03-TL-375-038: A Phase II Safety Study ofTAK-375 in
Subjects with Mild to Moderate Chronic Obstructive Pulmonary Disease.
Sanofi-Synthelabo EFC5202: Evaluation of the Hypnotic Properties of
Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared
to Placebo in Patients with Primary Insomnia. A Double- Blind,
Randomized, Placebo-Controlled, Three Way Cross-Over Study.

2002

GlaxoSmithKline 101468/191: A 12 Week, Double-Blind, PlaceboControlled Parallel Group Study to Assess the Efficacy, Safety and
Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS)
Suffering from Periodic Leg Movements of Sleep (PLMS).
Sanofi-Synthelabo EFC4529: Comparison of Efficacy and Safety of
Zolpidem-MR 12.5mg and Placebo in Patients with Primary Insomnia. A
Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study.
Neurocrine NBI34060-MR-0212: A Phase III, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess
the Efficacy and Safety of a Modified Release Formulation ofNBI-34060
in Elderly Primary Insomnia Patients with Sleep Maintenance
Difficulties.
Takeda 375-022: A phase III, Open-Label, Fixed Dose Study to
Determine the Safety of Long-Term Administration ofTAK-375 in
Subjects with Chronic Insomnia.
GlaxoSmithKline 101468/243: A 52 Week, Open-Label Extension Study
of the Long-term safety and tolerability of Ropinirole in Subjects
with Restless Legs Syndrome (RLS).

2001-2002

Sepracor 190-047: A Randomized, Double-Blind, Placebo-Controlled
Parallel, Two-Week Objective Efficacy and Safety Study of Esopiclone
in Elderly Subjects with Primary Insomnia.
Takeda 375-005: An Efficacy, Safety, and Dose Response Study of
TAK-375 in Subjects with Chronic Insomnia.

2000

Sepracor 190-046: A Randomized Double-Blind, Placebo-Controlled
Parallel Study of the Efficacy and Safety of (S)-Zopiclone in the
Treatment of Adult Subjects with Primary Insomnia.
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